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Abstract 
Neurodegenerative diseases (NDs), the most prominent example of which is Alzheimer’s disease (AD), 
has turned out to be among the greatest challenges for modern medicine. Common characteristics of 
NDs involve the aggregation of proteins, progressive loss of neuronal cells in specific regions of the 
central nervous system (CNS) and as a result – cognitive and/or functional decline. Another common 
feature of most NDs is an extended prodromal stage, in the case of AD believed to be initiated over a 
decade ahead of noticeable symptoms. Finally; atypical disease presentation and a high frequency in co-
morbidities means that specific NDs are generally difficult to define and distinguish. Research would 
therefore benefit greatly from new biomarkers that can aid in diagnosis, be used for monitoring disease 
progression, and provide insight into the disease mechanisms. As new disease-modifying therapies are 
being developed, for example against AD, there will be an increased need for biomarkers that enable 
earlier and more accurate diagnosis and response to treatment.           
Analysis of cerebrospinal fluid (CSF) is valuable to the study of NDs. A multitude of molecules shed 
by cells are deposited in the CSF, and thus, many processes in the CNS are dynamically reflected in the 
molecular composition of the CSF. Previous studies have revealed that CSF, besides proteins, contains 
many endogenous peptides. Being the products of a variety of processes, such as enzymatic protein 
processing, secretion, and aggregation, these peptides may convey valuable biomarker information.  
From an analytical point of view, endogenous peptides are attractive: circumventing proteolytic 
digestion eliminates a source of analytical variability, and reduces cost and sample preparation time, 
which are important aspects for establishing assays for clinical research and routine settings. 
Furthermore, endogenous peptides can readily be isolated from the high-abundant proteins that make up 
the bulk of the CSF protein contents, by for instance molecular-weight ultrafiltration, thereby allowing 
a larger volume of CSF peptide extract to be used for LC-MS analysis, improving chances to detect low-
abundant peptide species. 
The initial aim of this thesis was to develop and optimise methods for isolation, separation, detection 
and identification of endogenous CSF peptides, with a special focus on low-abundant species. Further, 
strategies for improved data utilisation and quantitative analysis were also evaluated and subsequently 
implemented with the goal of identifying endogenous CSF peptide biomarker candidates from clinical 
cohorts. 
Our studies have shown both that the endopeptidome of human CSF is substantially larger than 
previously indicated and containing a large number of peptides originating from proteins of noted 
interest in the study of NDs. Further, by means of extensive sample preparation and improved data 
analysis-techniques we were able to identify a multitude of potential biomarker prospects and, most 
importantly, three novel biomarker candidates for AD of validated diagnostic value.  
More studies are required to further evaluate the identified biomarker prospects for diagnostic value as 
well as to investigate what their respective presence in CSF may tell about various processes in the CNS. 
However, the studies included in this thesis have shown that the CSF endopeptidome is a source of 
information into neurodegeneration with great potential.    
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Sammanfattning på Svenska 
Neurodegenerative sjukdomar, av vilka det mest kända exempel är Alzheimers sjukdom, är bland de 
största utmaningarna för modern läkevetenskap. Gemensamma karakteristika för gruppen involverar 
proteinaggregering, progressiv förlust av nervceller i sjukdomsspecifika delar av det centrala 
nervsystemet och som ett resultat därav – förlust av kognitiv förmåga samt funktionsnedsättning. Ett 
annat gemensamt kännetecken av de flesta neurodegenerative sjukdomar är en lång pre-symptomatisk 
period, Alzheimers sjukdom tros till exempel inledas årtionden innan dess att märkbara symptom 
uppstår. Slutligen, icke-typisk sjukdomsprocess och en hög frekvens av komorbiditet resulterar i att 
neurodegenerativa sjukdomar generellt är svåra att både diagnosticera och särskilja från varandra. För 
att förbättra möjligheten att studera den här gruppen sjukdomar behövs nya biomarkörer för diagnos, 
prognos samt för att kunna observera sjukdomsförloppet och mekanismer involverade i dess utveckling. 
När nya behandlingar nu börjar dyka upp kommer det även behövas biomarkörer för en tidigare och 
säkrare diagnos samt för att kontrollera behandlingens effekt.          
Cerebrospinalvätska (eller likvor) är ett av de mest använda provmaterialen i studien av 
neurodegenerativa sjukdomar. En stor mängd molekyler utsöndras till cerebrospinalvätskan från celler 
i det centrala nervsystemet vilket innebär att processer i hjärnan reflekteras i större eller mindre 
utsträckning i cerebrospinalvätskan. Det innebär även att man kan använda cerebrospinalvätska för 
observation av det centrala nervsystemet. Tidigare studier har påvisat att cerebrospinalvätska utöver 
proteiner också innehåller en stor mängd endogena peptider. De endogena peptiderna tros vara ett 
resultat av en rad olika processer i det centrala nervsystemet och kan således möjligen vara en potentiell 
källa till biomarkörer. 
Från ett analytiskt perspektiv är endogena peptider intressanta eftersom de tillåter en mindre komplex 
provpreparation som undviker diverse potentiella felkällor vilka är viktiga aspekter att ta hänsyn till när 
man försöker utveckla metoder för klinisk rutinanalys. Vidare så kan endogena peptider isoleras direkt 
från cerebrospinalvätska med hjälp av olika separationsmetoder, som till exempel 
molekylviktsfiltrering, vilket även medför att man avlägsnar stora delar av proteininnehållet. Genom att 
på detta sätt exkludera proteiner från provet kan man använda en större volym cerebrospinalvätska, 
vilket i sin tur innebär att en större mängd endogena peptider ingår i efterföljande masspektrometrisk 
analys och att lågförekommande peptidspecier således har större chans att detekteras.     
Det primära målet i denna avhandling var att utveckla och optimera metoder för att studera endogena 
peptider i cerebrospinalvätska, med en speciell fokus på lågförekommande specier. Strategier för 
förbättrat utnyttjande av data och för kvantitativ analys utvecklades och implementerades för ändamålet 
att identifiera biomarkörkandidater bland de endogena peptiderna från kliniska kohorter. 
Våra studier har visat att endopeptidomet i mänsklig cerebrospinalvätska inkluderar ett betydligt större 
antal peptider än tidigare visats, och även att många proteiner av intresse i forskning om 
neurodegenerativa sjukdomar representeras av endogena peptider. Vidare så har vi, tack vare de metoder 
för provpreparation och analysteknik som utvecklats kunnat identifiera en lång rad potentiella 
biomarkörkandidater. Slutligen, tre biomarkörer för Alzheimers sjukdom har identifierats och 
utvärderats i kliniska material, med påvisad diagnostisk förmåga. 
Fler studier behövs för att utvärdera den kliniska nyttan av de potentiella biomarkörkandidater vi 
identifierat samt för att undersöka vilka processer i det centrala nervsystemet som resulterar i just dessa 
peptider. Det går dock att säga från de studier som här har utförts att endogena peptider i 
cerebrospinalvätska är en källa till information om neurodegenerativa sjukdomar av stor potential.            
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1. Introduction 
As the average human life expectancy keeps increasing globally, disorders correlating with age, such as 
neurodegeneration, follow suit [1, 2]. The consequence of this relationship is that an expanding part of 
the population lives longer with one or several conditions, that renders them incapable of normal life 
and function, causes a great deal of suffering and represents a big expense for society.  
The root cause of most neurodegenerative disorders (ND), e.g., Alzheimer’s disease (AD), Parkinson’s 
disease (PD) and dementia with Lewy bodies (DLB), are unknown. Diagnosis is commonly impeded by 
a lack of defined clinical parameters; a deficiency largely stemming from many NDs presenting 
overlapping pathological manifestations as well as comorbidity, particularly common in AD patients 
[3]. Thus, there is a need for novel diagnostic tools and biomarkers in the diagnosis, differentiation, 
study and treatment of neurodegeneration. A precise and early diagnosis would have a great impact on 
a number of conditions within the realm of neurodegenerative disorders [4-8]. 
In the case of neurodegeneration, cerebrospinal fluid (CSF) is arguably the preferred diagnostic material. 
Proximal to the brain, CSF contains a complex mixture of thousands of proteins, peptides, metabolites, 
salts and a wide range of other components of which approximately 20% of the mass is derived from 
the central nervous system (CNS) [9, 10], while the remaining 80% comes from the blood. Furthermore, 
CSF is in a constant flux with a turnover rate that exchanges the entire volume approximately 3-4 times 
per day, resulting in responses to stimuli in the brain being possible to detect quite rapidly [9, 11]. The 
usefulness of CSF for the development of novel biomarkers has been demonstrated for AD where a 
combination of altered CSF concentrations of phosphorylated tau (P-tau), total tau (T-tau) and amyloid-
β (Aβ) are 85-95% sensitive and specific for Alzheimer´s disease, both at the prodromal and dementia 
stages [12]. However, even though there are some candidates under investigation for other NDs [13, 
14], so far only AD has been coupled with defined biomarkers. Yet, AD is a heterogeneous disease with 
a high incidence of atypical presentation and co-morbidities, and the need for both diagnostic and 
differential diagnostic markers is therefore still great, as with all other NDs. 
Since the mid-eighties, progress in mass spectrometry (MS) has led to the technique becoming more and 
more prominent in the study of complex samples and discovery of novel biomarkers [15, 16]. In 
particular the development of “softer” analyte ionisation methods, such as electrospray ionisation (ESI) 
[17, 18] and matrix-assisted laser desorption ionisation (MALDI) has improved the capabilities of 
studying proteins and peptides [17, 19-21]. From there, the evolution of MS has accelerated to a point 
where instruments are able to identify thousands of proteins from a single biological sample in the 
microgram-range are used by many facilities. This, in-turn, has resulted in the possibility of using MS 
for non-hypothesis driven, or explorative, purposes and thereby introduced (or at least accelerated) the 
field of proteomics which has revolutionised many areas of biology [22]. In the clinical area however, 
the progress has been slower; despite almost two decades of proteomic studies of NDs, proteomics has 
contributed relatively few – if any – new biomarkers to clinical research [3, 13]. This may indicate that 
proteomic methods and analytical strategies need further development, or simply that a degree of 
maturation of any field of science is necessary – i.e., researchers need to get the hang of the technology.  
The concept of “omics”, as in “genomics” and “proteomics”, in biology refers to the exhaustive study 
of a particular set of molecules and their role in a biological process, tissue or whole organism. In 
proteomics the general aim is to study protein expression, structure and function from observations of 
various sample materials such as blood, urine, CSF, cell cultures or tissue biopsies [22]. This thesis 
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another type of omics will primarily be discussed, “peptidomics” or “endopeptidomics”, in which the 
endogenous peptides present in biological samples are in focus, rather than the proteins from which they 
derive [23]. There is a discussion on whether peptidomics should be considered a stand-alone subject or 
be part of the proteomics sphere, a debate that may be regarded purely academic in either case. However, 
endogenous peptides are ubiquitous in biological systems, sometimes as biologically inert entities, i.e., 
waste resulting from degradation of proteins, but biologically active peptides are also a vital part of 
homeostasis [23-25].  
In conclusion, the main goal of this thesis was to evaluate the peptidome of CSF as a viable source of 
biomarkers for NDs. To this end, methods and protocols for efficiently isolating, detecting, identifying 
and quantifying endogenous CSF peptides in both pooled material and clinical cohorts were developed 
and employed. The results of all trials performed were a substantial increase of the known constituents 
of the CSF endopeptidome and importantly, the discovery and evaluation of three potential biomarkers 
for AD, as well as a large number of not-yet evaluated biomarkers prospects. Furthermore, the methods 
and protocols themselves; developed for the study of endogenous peptides in CSF but with minor 
alterations applicable for future studies also in other sample materials. 
1.1. Neurodegenerative diseases 
Neurodegenerative diseases (NDs) include both dementias and movement disorders. They embody a 
large and, in many aspects, heterogeneous group of pathophysiological and mental conditions. The 
DMS-5 (Diagnostic and Statistical Manual of Mental Disorders), published by the American Psychiatric 
Association, defines dementia as a significant decline in one or several aspects of cognitive performance 
which negatively impacts daily life and function [26].   
Dementia is considered among the top healthcare challenges of today and tomorrow, currently affecting 
nearly 50 million individuals worldwide and surpassed only by the care and treatment of cancer in cost 
to society [27, 28]. The number of studies involving the various states of dementia and the amount of 
funding invested [29] have so far not yielded either a cure, or even any definitive pathophysiological 
mechanisms. However, novel biomarker candidates are emerging along with an ever-improving ability 
to study the subtle and intricate mechanisms acting in the human CNS.   
1.1.1. Definition and characteristics 
NDs are characterised by progressive loss of neurons and/or supporting cellular structures in specific 
regions of the CNS [26, 30-34]. The causes for this selective cell death are still largely obscure in the 
case of most NDs. A common feature is the aggregation of proteins or peptides into insoluble bodies. 
The role of these aggregates is still debated, although the constituents of the aggregates seem somewhat 
disease-specific and thus suggest an involvement in the pathophysiological process [35-37]. Each 
particular ND is further characterised by the area of the CNS primarily affected and thereby by the 
associated symptoms. However; problems in defining and diagnosing specific disorders stem from 
frequently occurring co-morbidities as well as large variations in pathological and clinical manifestation 
[38]. Further, atypical presentation of symptoms or symptoms correlating poorly with the extent of 
pathophysiological progression are relatively common, making neurodegeneration both difficult to 
diagnose and to study. The latter is an interesting phenomenon suggesting an apparent resistance to 
dementia in some patients. It has been referred to as the “cognitive reserve” and allow individuals to 
largely avoid or at least postpone the effects of neurodegeneration [39, 40].   
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Although there are a few notable exceptions, such as amyotrophic lateral sclerosis (ALS) and 
Creutzfeldt-Jakob disease (CJD), most forms of ND correlate with age. Above the age of 60, an 
estimated 5% of the population are diagnosed with AD and the prevalence increases exponentially from 
then on [41].   
1.1.2. Alzheimer’s disease 
The form of dementia subsequently known as AD was first described in the beginning of the 20th century 
by Alois Alzheimer as a disorder with progressive memory loss and eventual disruption of executive 
function affecting the ability to perform normal and basic activities [42, 43]. Alzheimer further described 
the distinct pathophysiological traits after post-mortem examination of a patient, which today are known 
as senile plaques, neurofibrillary tangles and extensive cerebral atrophy. However, it was a former 
colleague of Alzheimer, Emil Kraepelin, who eventually named the disorder after Alzheimer, after the 
death of the latter in 1915. 
Interestingly, in the original article “Über einen eigenartigen, schweren Erkrankungsprozess der 
Hirnrinde” (roughly: About a peculiar, severe disease of the cerebral cortex), Alzheimer discussed the 
problem of discerning and discriminating between the disease which came to bear his name and other 
forms of senile dementia [42]. Co-morbidity is still considered one of the key issues in AD diagnosis 
and ways to improve its accuracy are in demand for future diagnostics and scientific purposes.   
AD is now known to be the most common form of ND It corresponds to roughly 70% of dementia cases 
and affect approximately 50 million people worldwide (2016). The disease has a noticeable impact on 
the gross world product with a direct cost to society comparable to the Swedish national budget [2, 27]. 
The actual cost is most likely much higher since the disease also directly and indirectly affects 
individuals with relations to the patient. 
Memory and executive dysfunction in individuals above 65 years is the most well known manifestation 
of AD. However, atypical cases involve distinctly younger individuals, commonly 50-60 years old, and 
may affect language, vision and/or executive function prior to noticeable impact on memory [44, 45]. 
Being the most ubiquitous of neurodegenerative disorder resulting in age-related dementia, AD has been 
extensively studied for nearly 60 years without any breakthrough in treatment (except for symptomatic 
treatments that do not modify the underlying disease process) or prevention so far [46]. This can partly 
be attributed to a lack of diagnostic and predictive biomarkers, due to which clinical trials are difficult 
to conduct. However; because of the improved ability to study complex biological systems, as shown in 
this thesis, one can hope/expect this issue to be remedied  [47].  
1.1.2.1. Pathological manifestations and symptoms 
The neuropathological hallmarks of AD include extracellular senile plaques mainly consisting of 
deposits of amyloid beta 1-42 (Aβ1-42) and intraneuronal fibrillary tangles of hyperphosphorylated and 
truncated microtubule-associated protein tau (MAPT or tau) [2, 48-50]. AD pathology presents a 
complex pattern, the intricacies of which are still largely unknown and debated.  
Among the more influential and widely considered/accepted pathological pathways is the so called 
‘amyloid cascade hypothesis’ (ACH) [51]. Briefly, the AD pathogenesis scenario in the ACH is 
suggested to be initiated as a consequence of increased production and aggregation of the Aβ1-42 peptide 
[52]. Initially this increase was believed to be a result of mutations either in the gene coding for amyloid 
precursor protein (APP) itself and/or the genes coding for presenilin 1 (PSEN1) and presenilin 2 
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(PSEN2), both involved in the processing of APP [53]. However, although said genetic factors have 
been recognized as major effectors in early-onset familial AD, it seems as if sporadic AD is less straight 
forward and that other mutations and genetic risk factors such as the APOE ε4 allele [54-56], as well as 
other mechanisms may be involved [57, 58]. Independent of its derivation, the neurotoxic effects of 
upregulated Aβ1-42 production is believed to result from both small soluble oligomers and from larger 
depositions (i.e., plaques) [59, 60], albeit that the exact mechanism(s) of toxicity is still poorly 
understood [61, 62]. The accumulated toxic effects (sometimes referred to as “aggregated stress”) 
eventually affects other systems, among them neuronal processing and regulation of microtubule-
associated protein tau, resulting in aggregation of the same into paired helical fragments and 
neurofibrillary tangles [62, 63]. The aggregated stress, possibly added to by the presence of tangles, 
eventually results in neuronal loss, cognitive impairment, dementia and finally death [62]. The ACH has 
received criticism for not sufficiently explaining some of the mentioned key effectors and mechanisms, 
but the ACH still manages to provide a causal pathway within and around which further research can be 
performed to either support or ultimately falsify the hypothesis.  
Irrespective of the exact pathogenesis, typical (or sporadic) AD pathology involves loss of neuronal 
cells, initially in the temporal lobe where hippocampus and entorhinal cortex are primarily impacted [2, 
64, 65]. Because of the areas affected, the most noticeable early symptom is impaired episodic memory 
followed by loss of other cognitive functions such as language comprehension and formulation, which 
gets steadily more severe as the disease progresses. Progressive loss of neuronal function eventually 
results in the patient ending up in a completely vegetative state. Death results either from secondary 
conditions such as respiratory infections (pneumonia) or stroke, or as a direct consequence of 
dysregulation of life sustaining functions; cause of death in the latter case put down simply as 
“dementia/senility” [66, 67]. 
1.1.2.2. Diagnosis 
In 2014, the International Working Group (IWG) together with the US National Institute on Ageing-
Alzheimer’s Association (NIA-AA) updated their previously defined criteria for the diagnosis of AD 
[64, 68]. The updated version redefines the concept of dementia but takes into account the previous 
definition of probable AD based on clinical evaluation focused on cognitive dysfunction, impaired 
memory and, importantly, the absence of co-morbidities [69, 70]. The main alteration in the updated 
criteria is the suggestion of introducing neurochemical and neuroimaging diagnostic markers to study 
two separate biological processes of AD; plaque pathology and neuronal damage [70]. A low 
concentration of CSF Aβ1-42 and a positive signal on amyloid positron emission tomographic (PET) 
imaging indicates plaque pathology [71-73]. The extent of neuronal damage is indicated by elevated 
CSF concentrations of total tau protein (T-tau) and hyperphosphorylated tau (P-tau), and reduced 
fluorine-18 fluorodeoxyglucose ([F18 ]FDG) uptake in the temporoparietal cortex [74]. It should be noted 
that the criteria involving the employment of diagnostic markers for AD specify use only for research 
purposes, meaning that implementing said biomarkers in clinical routine analysis is not yet 
recommended.  
The CSF concentrations of the above-mentioned molecules, and the presence indicators measured by 
neuroimaging techniques, i.e., PET, are considered “core feasible” biomarkers of AD [75]. The term 
means that these biomarkers are not only well defined for the purpose of diagnosing AD but are also 
capable of measuring specific aspects of the extent of neurodegenerative progression and may be 
possible to employ in preclinical stages of the disorder as well [75-77].   
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1.1.3. Diagnostic challenges 
The diagnosis of NDs is generally considered difficult and often relies on the employment of a plethora 
of complementing diagnostic tools, over a period of time, to reject or confirm a certain disorder [78]. 
The diagnostic challenges result from the slow and stealthy progression of most NDs and the 
presentation of atypical symptoms [13]. This is often exacerbated by variation in disease definition, 
which makes differentiation of disorders difficult.      
Several NDs, e.g., AD, frequently present co-morbidity in pathological manifestation; for instance, AD 
often develops alongside other sources for cognitive decline such as dementia with Lewy bodies (DLB) 
and vascular dementia [13]. The ability to identify individuals likely to develop neuropathology in later 
life is key for successfully studying this class of diseases [64]. A number of genetic variations that 
correlates with an increased risk of developing an ND have been identified [56, 79-81]. Unfortunately, 
the current diagnostic markers for AD (the only established biomarkers for any ND) do not correlate 
well with the earliest clinical and cognitive symptoms of the disease, known as mild cognitive 
impairment (MCI) [64, 82].  
Atypical presentation of AD is another challenge because it may involve the presence of the classical 
plaque-tangle pathology, but cognitive functions remain largely intact. There are also subtypes of the 
disease which are still considered AD, but that are predominantly affecting other areas – such as primary 
age-related tauopathy (PART), which mainly affects the limbic system leaving hippocampus relatively 
unaffected [83]. 
1.1.4. Why do we need more biomarkers of NDs 
In theory, a biomarker can be any characteristic, that may be employed to assess the state of a biological 
system. Biomarkers are used in diagnosis, prognosis, monitoring of disease progression and target 
engagement for drug treatment in a clinical setting, or to characterise and explore biological systems for 
primarily scientific reasons [84].  
Due to the progressive and often slow disease development combined with a high frequency of co-
morbidities, atypical presentations and individual resistance results in NDs in general and AD in 
particular being hard to diagnose accurately. The clinical diagnosis can still only be confirmed after 
post-mortem examination of the patient’s brain [85].  
There are currently few biomarker candidates for NDs; only for AD have reliable biomarkers been 
established [12], making the selection of individuals for clinical trials both difficult and error prone. 
Cohorts commonly contain a number of false positives and negatives, which hampers the study of this 
category of disorders [13, 86].  
The current hypothesis is that the majority of NDs are initiated long before the first noticeable 
symptoms– meaning that it is only towards the later stages that the disease is diagnosed, with 
confirmation commonly achieved until post-mortem examination. However, even though a number of 
genetic risk factors have been identified [79, 87-89], there is currently no reliable way of telling whether 
someone will develop an ND later in life.  
1.2. Cerebrospinal fluid  
Examination of cerebrospinal fluid is employed as a pathway for observation of chemical changes within 
the CNS. CSF is the recipient of a large number of molecules shed by cells in the CNS and is therefore 
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considered to at least partially reflect many of its processes [10, 90]. However; for MS-based proteomic 
analysis, CSF also presents an analytical challenge; the concentrations of protein/peptide species in the 
CSF span between eight and nine orders of magnitude and it is reasonable to assume that the 
diagnostically relevant markers are present in the lower end of this range [91]. Compared to for instance 
an immunoassay, in which the target proteins are selectively isolated and detected, explorative clinical 
proteomics is designed to detect the entire protein complement of a sample and to subsequently attempt 
to determine each peptide’s diagnostic value. 
1.2.1. Source 
It is hypothesized that the bulk of CSF is produced in the choroid plexus and that interstitial fluid from 
the surrounding nervous tissue contributes by draining into the CSF [9, 92]. Besides acting as a transport 
pathway for various CNS products, as CSF surrounds the entire brain and fills grooves and cavities, the 
fluid also functions as a stabilising medium and offers cushioning support in the event of impact or other 
forms of trauma. CSF is considered an “ultrafiltrate of plasma” since it is largely derived from fluid 
passing over the blood brain barrier (BBB). However, it also contains a large amount of products and 
waste from the CNS, i.e., proteins, peptides, salts, neurotransmitters and cell debris, which is produced 
locally [90, 93, 94]. With a high turnover-rate of the latter (~500 mL per day in healthy adults) both 
major and minor events in the CNS are soon reflected in, and can be monitored through, the CSF [95, 
96]. Traumatic brain injury (TBI) such as being knocked out in boxing shows up in CSF as an increase 
of various intracellular neuronal proteins (e.g., tau) over a period of a few weeks    
1.2.2. Sampling 
Cerebrospinal fluid is extracted by means of lumbar puncture, which is a safe procedure with post-
lumbar puncture headache as the only potential complication occurring in 2-20% of patients (varying 
rates across studies) [97], but the only study done in a blinded fashion (comparing actual with sham 
lumbar punctures) found no difference in rates of headache [98]. Twelve mL of CSF per patient was 
extracted via a needle inserted into the dural space between lumbar vertebrae L3/L4 or L4/L5 according 
to a standardised procedure. The CSF was collected in polypropylene tubes, insoluble material was 
subsequently removed by centrifugation at 2000 g and 4 °C for 10 min followed by transfer and 
aliquoting of the supernatant into new tubes. The CSF was finally stored at -80 °C. 
1.2.3. CSF biomarkers 
Although there is currently no diagnostic biomarkers for any ND fully implemented in clinical routine 
analysis, the biomarkers for AD described in this chapter have been extensively studied and 
characterised for this research purpose [12, 77, 86]. The question is hence ‘when’ rather than ‘if’ these 
neurochemical markers will be employed, or at least accepted, globally in a clinical setting.   
1.2.3.1. Amyloid β peptide 1-42  
Aβ1-42 is a pathophysiological biomarker for amyloid pathology measured in CSF and is used for 
indicating the presence and extent of senile plaque formation in the CNS. The Aβ1-42 peptide is the result 
of sequential proteolytic processing of the transmembrane amyloid precursor protein (APP) by β-
secretase (BACE) followed by γ-secretase, referred to as the amyloidogenic pathway [99]. In a study 
published in 2011 by Portelius et al. it was shown that CSF contains a large number of APP fragments, 
indicating that the processing of APP is complex and that several mechanisms for its proteolysis are at 
work [100]. The APP family of proteins have been extensively studied (primarily in various mouse 
models) over the past decades [101]. The proteins are highly expressed in neurons and are upregulated 
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during neuronal differentiation and maturation [102]. Other than that the exact function of APP is 
unknown. There is little evidence of APP itself being involved in AD pathological process. It is rather 
the dysfunctional (pathological) processing that results in increased concentrations of Aβ1-42 correlating 
with AD pathology.   
Studies have shown that, in individuals with atypically high or low total CSF concentration of Aβ 
peptides, Aβ1-42 may better correlate with the total Aβ peptide concentration and therefore result in a 
mis-diagnosis [103, 104]. Aβ consisting of 40 amino acids (Aβ1-40) is the most abundant Aβ peptide in 
CSF and is generally believed to be non-pathological. By employing the Aβ1-42/Aβ1-40-ratio it is possible 
to compensate for variations in Aβ peptide concentration levels resulting from processing of APP and 
this may potentially lead to a more precise diagnosis [103, 104]  
1.2.3.2. Total tau (T-tau) 
Microtubule-associated protein tau has a range of functions for assembly, as transient stabiliser and as 
mediator of transport functions, all connected to the intracellular microtubule network [105]. The protein 
is predominantly expressed in neurons, in a substantially higher degree in the non-myelinated cells of 
the neocortex (grey matter) as compared to those in the cerebellum and myelinated cells of white matter 
[106, 107]. The function of the protein is associated with its degree of phosphorylation (see the next 
section) but it has been suggested that tau is also dependent on its ability to oligomerise in order to form 
essential interactions [108, 109].  
An accumulating body of literature indicates the involvement of specific tau forms and modifications in 
neuronal dysfunction and pathologies [110]. A key study, in which large volumes of CSF were 
fractionated by high pressure/performance liquid chromatography (HPLC) and analysed by western blot 
using different antibodies, revealed the presence of a multitude of N-terminal and mid-domain tau 
fragments [111]. Several of these fragments appeared to differ in abundance between AD patients and 
controls, indicating that the tau molecular heterogeneity, reflected in the CSF may contain important 
biomarker information.   
The total CSF concentration of tau protein (or protein fragments containing the respective antibody 
epitopes) referred to as “T-tau” is a marker of neuron axonal damage [112-116]. This means that T-tau 
is not specific to AD or even neurodegeneration, but correlates well with the extent of brain injury and 
neurological damage [77, 117]. The protein concentration in CSF increases when the microtubule-
transport system and neuronal cell membrane is disrupted, e.g. due to disease or trauma. In AD, T-tau 
is therefore employed to measure the intensity of neuronal degradation. However, considerably elevated 
levels of T-tau can also be seen as a consequence of more rapidly progressive NDs such as CJD [118] 
and in acute traumatic brain injury [117, 119]. Hence, T-tau needs to be complemented by other markers 
to allow for a more specific diagnosis.  
1.2.3.3. Phosphorylated tau (P-tau) 
The function of tau is to modulate microtubule assembly, to enable microtubule-based axonal transport 
in neurons and to be one of the means of cellular structural dynamics [120-122]. The functionality of 
tau for these purposes is dependent on both stable and transient phosphorylation of specific sites by one 
or several protein kinases [122], which reduces tau’s microtubule-binding ability (or affinity) along with 
its ability to stabilise the polymers, allowing for dismantling and restructuring of the microtubule 
network [123, 124]. An interesting model for tau’s cellular function, both as a stabiliser of microtubules 
and mediator in axonal transport, but also for other forms of signal transduction [125], is a behaviour 
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known as “kiss-and-hop” [126], where the interaction between tau and particular microtubule is around 
40 µs long after which tau moves on to another interaction.  
A prime candidate for the role as tau “phosphorylator” is glycogen synthase kinase 3β (GSK3β), which 
has been shown to both co-localise with the protein [127, 128] and to employ tau as a substrate [129-
131]. Overexpression of GSK3β in mouse models correlates with an increase in the phosphorylation in 
a number of sites, possibly indicating the involvement of GSK3β, or another protein kinase, in the 
pathologic phosphorylation of the tau protein [122].    
Tau phosphorylation is key to both the function and dysfunction of the protein [132]. The presence of 
truncated and hyperphosphorylated tau in neurofibrillary tangles (NFTs) suggests that at some point, for 
some reason, the regulation of tau phosphorylation becomes dysfunctional, resulting in an inability to 
bind to microtubules and to carry out its normal tasks [133]. It is unknown whether the NFT aggregates 
are the result of spontaneous formation (possibly due to the high degree of phosphorylation or as a result 
of failed clearance [51, 134]), whether they are actively formed as part of an immune system response, 
or whether there is a completely different mechanism [116, 133-136]. Either way, an increase in the 
CSF concentration of P-tau correlates with AD pathology [137], and is for that reason employed as a 
biomarker for the same.    
1.2.4. Biomarker candidates 
The section below describes a number of promising biomarker candidates currently under investigation 
for their potential applicability for the diagnosis of neurodegeneration.   
1.2.4.1. Neurofilaments 
The neurofilaments (NFs) are a type of intermediate filament and one of the triad of polymeric filaments 
(along with microtubules and microfilaments) that constitute the so called cytoskeleton1 of neuronal 
cells [139]. Differing from the other two filaments, NFs are exclusively expressed in neurons and are 
especially well represented in large myelinated ditto [140], where it is the most prominent cytoskeletal 
protein [31].  
There are three subunits of NFs suitably named in order of ascending molecular weight; neurofilament 
light (NFL), medium (NFM) and heavy (NFH) chain. The initial expression of each subunit seems to 
correlate with the time-dependent requirements of the embryonic neuritic development [141]. The 
assembly of the NFs is still not well understood but it is believed that the first step involves dimerization 
of NFL followed by coupled polymerisation with either NFM or NFH resulting in a heteropolymer with 
structural properties depending on the ratio of NFL to NFM/NFH [142]. Neurofilaments have been 
reported not to assemble into proper filaments in vitro; a drawback since it does not allow to study NFs 
in tissue culture thereby hampering biomarker development [142] 
Neurofilament light concentration, similarly to T-tau, increases in CSF as a result of extensive axonal 
damage and can be employed as a complement to the same in diagnosis of AD [31]. Cerebrospinal fluid 
concentrations of NFL correlate well with AD pathology, increasing stepwise from healthy control (HC) 
                                                     
1 “Cytoskeleton” is an umbrella term for a number of different proteins which are to some extent tasked to function 
as a cellular scaffolding, giving structural support and rigidity to the cell. The name is somewhat misleading since 
the cells “skeleton” is also crucial in cellular transport and is, compared to its vertebrate namesake, a highly 
malleable and dynamic construct [138] Shay, J., the Cytoskeleton, Springer Science & Business Media 2013, [138] 
ibid.. 
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to MCI and from MCI to AD [86], however with some overlap between groups. What is most interesting 
is that NFL is detectable in plasma and further, is able to separate groups to a similar degree as in CSF 
[12, 143, 144]. However; NFL is not a good marker for differential diagnosis; NFL concentration in 
CSF can satisfactorily separate HCs and AD pathology-positive patients but does not allow for 
distinguishing between HCs and tau-positive patients, nor between AD and other neurodegenerative 
dementias [114].   
1.2.4.2. Neurogranin  
The calmodulin-binding protein neurogranin (Ng) is involved in long term potentiation/depression of 
dendritic spines by modulating Ca2+ concentrations in the synaptic cleft [145, 146]. Further, Ng is 
believed to affect neuronal plasticity and thereby cognitive function, but the mechanism by which Ng 
carries out this role is not fully understood [146].  
Synaptic dysfunction and depletion are pathophysiological traits of AD, and have been shown to be 
among the early steps of AD pathogenesis [54, 147-149]. The severity of cognitive impairment, as well 
as amyloid pathology have been shown in several studies to correlate well with the CSF concentrations 
of Ng [30, 150-153]. This suggests that biomarkers correlating with synaptic loss, such as Ng, could 
also be employed to indicate early onset of AD as well as, to some degree, severity and rate of decline 
of cognitive impairment [154, 155].  
Further, according to Wellington et al. (2018), the CSF concentration of the protein is elevated in typical 
AD compared to atypical cases (P=0.004), and is specific for AD compared to other NDs suggesting 
that Ng can be employed for differential diagnosis as well as for determining typical or atypical AD 
[156, 157]. 
1.2.4.3. Chitinase-3-like protein-1 
Chitinases constitute a group of glycoside hydrolases with the primary function of degrading chitin2 
[159]. In mammals the chitinases are expressed in various cell types, most likely as a defence against 
parasitic insects, fungi and helminths by challenging them when present in the body and to reduce the 
inflammatory response and allergic reaction induced [160]. In addition to chitinases, mammals also 
express a group of enzymatically inactive, but structurally similar chitinase-like proteins (CLPs). Their 
exact biological function is unknown, but evidence suggests that they are involved in immunoregulation 
[161, 162]. Chitinase-3-like protein-1, also known as YKL-40, is significantly upregulated (in what 
source depending on specific condition) in patients with asthma/allergy, infections from certain bacteria, 
arthritis and various fibrotic-disease [161, 163] as well as in a number of inflammatory conditions and 
cancer [164-166].   
YKL-40 has previously been suggested as a marker for TBI and multiple sclerosis [165, 167] but is now 
being evaluated as a novel CSF biomarker for other types of neurodegeneration, including AD [168-
170]. Tests indicate that, although YKL-40 primarily increases with age, it also correlates with AD, 
FTLD, and vascular dementia [171], importantly without a similar correlation with PD [170, 172]. Thus 
YKL-40 is potentially useful for differential diagnosis as well as indicating that AD and PD cause 
different neuroinflammatory responses.    
                                                     
2 Chitin is the main constituent of the exoskeleton and cell wall of arthropods, nematodes and fungi. Chitin is one 
of the most commonly occurring natural polymers on Earth, surpassed in abundance only by cellulose [158] 
Tharanathan, R. N., Kittur, F. S., Chitin—the undisputed biomolecule of great potential. 2003, [158] ibid. 
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1.3. Proteomics 
In order to overcome the various issues, old and new, involved in studying biological sample materials 
the field of proteomics is continuously introducing new analytical strategies or is updating older ones. 
Favourite techniques emerge and fall out of favour in the scope of a few years, just to be re-invented or 
simply return to fashion and make a comeback. The analytical approaches employed in the work 
performed in this thesis are described in detail in other sections, but a brief introduction to the main 
proteomics strategies is included in the section below. 
1.3.1. Shotgun proteomics 
In shotgun proteomics the building blocks of proteins are studied to gain information on the larger 
structure, a concept known as “bottom-up proteomics”. Initially the whole protein content of a biological 
sample material is degraded with proteolytic enzymes into peptides, which are subsequently separated 
over an HPLCcolumn and analysed by MS. Following analysis, the data is most commonly processed 
by a proteomics software. The software translates the analytical information (e.g. intensity, mass and 
charge of detected ions) from individual ms/ms-spectra to peptide-sequences [173]. The peptides, in 
turn, infer information on the proteins originally present in the sample – that is, the presence of a certain 
set of peptides (or just a single unique peptide sequence) detected by the MS indicates that the sample 
contained a particular protein [22, 174, 175]. 
The main reason for taking this seemingly roundabout route to study proteins is that the typical full-
length protein is quite a massive molecular structure; difficult to separate, ionise and fragment 
efficiently. Relatively novel techniques do allow for top-down proteomics by MS; however, extensive 
sample preparation and separation as well as MS method optimisation requirements makes for low 
throughput [175]. In comparison, degrading the proteins into bite-sized peptides ensures relatively 
straight-forward preparation, standardised HPLC separation and that a large section of the analytes is 
ionised and available for MS analysis. 
The shotgun approach does however require a considerable amount of already available information. 
This is because most proteomics software carrying out peptide identification employ peptide libraries 
for comparison with analytical data [174]. The libraries are created by performing in silico degradation 
of a known proteome (e.g. the human CSF proteome). Virtual peptides are generated through simulating 
protein cleavage corresponding to that resulting from the specific proteolytic enzyme employed for 
degrading the proteins in the actual sample. Databases containing the proteomes of whole organisms 
have been generated from genomic data. However; mutations, post translational modifications (PTMs) 
and splice variations requires these databases to be continuously updated and verified [176, 177].  
A number of techniques allowing for peptide and protein quantitation in shotgun proteomics have been 
introduced over the last two decades making proteomics much more useful in clinical studies [178-180].  
MS is not, as previously mentioned, an instrument that allows for quantitation unaided – i.e., by directly 
comparing signal output between different peptides within a sample or the same peptides between 
samples. The reason for this lack is the high variability stemming from various individual steps along 
the analytical path.  
Two main approaches to overcome this problem have crystallised: “Labelling-based” and “Label-free” 
quantitation. Labelling-based quantitation employs incorporation of heavy stable isotopes - either 
through in vivo metabolic integration by adding labelled amino acids to the diet, or chemically by 
labelling peptides in vitro during sample preparation [180]. The peptides in the labelled sample can then 
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be compared to their counterparts in an unlabelled or differently labelled sample and signal intensity can 
be used for relative quantitation (a step that requires extensive data processing by specialised, and 
expensive, software) [181]. In contrast the label-free approach relies on peptide peak area/height during 
chromatographic separation and spectral counting following MS/MS analysis for comparing analytes 
from different samples [182].  
All in all, shotgun proteomics has become the approach of choice for large scale proteomics studies due 
to its high throughput, ease of preparation and broad analytical range. Methods for relative quantitation 
has improved the usefulness of shotgun proteomics for studying protein/peptide expression and turn-
over, and made biomarker discovery a substantially simpler task.   
1.3.2. Targeted proteomics 
The previously described proteomics methods are primarily aimed at discovery-based studies and meant 
for allowing identification of large numbers of peptides and proteins from complex samples by 
employing elongated and multi-dimensional separation protocols. However, despite the introduction of 
several techniques for improving quantitative abilities of MS, absolute quantitation (i.e., exact 
determination of the concentration) still requires a fundamentally different approach, and may still not 
be absolutely achievable3  [183].  
The current methods for relative quantitation do not allow for determining exact concentration of 
analytes, but only the difference in quantity between samples. Targeted proteomics, as the name 
suggests, is the strategy employed when monitoring a set of pre-determined analytes, usually a 
comparatively small number relative to the whole proteome/peptidome of the sample material. 
Compared to other proteomics strategies, the point of targeted proteomics is to gather as much 
information as required to confirm the presence or to allow for concentration determination of the 
analytes [24, 184]. The latter is commonly made possible by introducing a standard of known quantity 
at some stage during sample preparation. The standard contains one or several amino acids carrying 
heavy isotopes, most commonly of carbon, nitrogen or oxygen. The result is a peptide identical in 
chemical properties but differing slightly in mass, meaning that it will co-elute, and most importantly, 
ionise at the same time and (ideally) to the same extent as the native peptide [185-187]. In essence; the 
two peptides are detected simultaneously but will be distinguishable by the mass difference. Hence, if 
the concentration of the standard is known the concentration of the native peptide can be determined by 
comparison [24, 183, 188, 189].  
Except for the addition of known quantities of an internal standard, the main difference is usually, as 
hinted, in the setting of the MS. The first MS-protocol step commonly involves ensuring simultaneous 
detection of the precursors of the sought after native peptide and its corresponding synthetic standard 
over their entire elution period [190]. Then, depending on the instrument, one or several fragments of 
each peptide are detected and subsequently employed for quantitation by comparison, usually of 
intensity over the period of detection (referred to as total peak area) [191-193]. The main difference lies 
                                                     
3 The question of whether absolute quantitation of complicated analytes using mass spectrometry is at all achievable is not 
going to be discussed here; it involves elongated discussions on chromatographic behavioural alterations resulting from 
differences in isotope-content and point-to-point (on milli-second scale) measurement variations of analyte versus internal 
standard concentrations during ionisation and mass analysis. Albeit extremely important, and enjoyable, to discuss the concept 
further in order to finally solve the problem, it is possible to consider the currently employed method for “absolute quantitation” 
sufficiently accurate for its purpose, e.g., to monitor concentration variations of peptides/proteins between samples to determine 
possible disease involvement.  
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in whether or not a single product ion is sufficient to identify the analyte or if several fragments are 
required.  
Except for the possibility of quantifying analytes, the main advantage is that the targeted approach 
usually requires short liquid chromatography (LC)-gradients and thus allows for high sample 
throughput. Depending on the instrument and the requirements to successfully identify the analytes, an 
analysis round may take only a few minutes and still allow for highly accurate and sensitive quantitation 
of the targeted analytes, providing there are not too many. 
1.4. Clinical proteomics 
The field of clinical proteomics is encumbered with the theoretically straightforward task of determining 
which proteins are expressed, to what extent, and how they are subsequently modified in healthy contra 
non-healthy individuals [194]. In essence, this means monitoring the total protein complement from 
cells, tissues, organs and whole organisms and even further, whole populations and population sub-sets, 
such as forgetful contra non-forgetful grandmothers [194]. This may yield both insights into disease 
mechanisms and lead to the development of tools for improved diagnosis, i.e., protein biomarkers and 
in the end to treatments and cures. Although it might seem an insurmountable enterprise the fact is that 
great progress has already been made.  
The field has advanced considerably with increased knowledge of biological systems to the development 
of ever-improving technical solutions which forms a positive feed-forward loop [195-197]. For instance, 
the enormous undertaking of the Human Genome Project impacted nearly every branch of biology as 
well as other sciences, a range of technologies were improved or developed and the collective 
understanding of information flow within living organisms was greatly enhanced [198, 199]. However, 
one of the greatest lessons was that the genome of an organisms says surprisingly little about its 
phenotype; that is, its actual protein expression [196]. An example of this increased divide between 
genome and proteome is found in nomenclature, where the original meaning of proteomics was “the set 
of proteins encoded by the genome” [200]. For this reason, a deal of focus has shifted towards improving 
the ability to study the proteome, employing genetic information to aid in protein identification, which 
in turn allows for an increasing understanding of gene-expression.  
The construction of databases for proteomics studies has largely been dependent on genetic information, 
to find out what proteins are expressed in a particular organism, tissue or cell type. [22, 194]. However, 
phenotypic information not inferable by solely studying the genome, or at least not directly inferable 
from the information derived from genomics (with our current capacity), e.g. post translational 
modifications, intra- and inter-protein interactions, enzymatic cleavage of proteins into bioactive 
peptides etc., must be derived through proteomic studies. This means that the proteome contains 
information on the functionality of an organism that currently stands separate from genomics [196].  
In clinical proteomics the focus is aimed at studying protein involvement in health and disease; 
discovering the difference in protein expression, modification and behaviour induced in individuals by 
a particular condition [194]. The purpose is to identify pathophysiological pathways, which in practice 
means that a particular sample material, believed to be closely involved in the disease process (or to 
reflect the process by proxy) is studied in detail and statistical analysis is perpetrated.  
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1.5. Peptidomics 
As with proteomics (and all other “omics”), the aim of endopeptidomics is to reach complete 
understanding of the “whole point” of the particular set of analytes, i.e., the endogenous peptides in a 
given organism. The fluxes in concentration depending on the state of the organism (age, health, sex, 
etc.) as well as their specific functions and interactions are all concepts sought to be understood [201-
203].  
Similar to the connection between genome and proteome, the link between proteome and peptidome is 
seemingly quite clear; that is, one results from the other. Endogenous peptides do result from proteins 
through proteolytic degradation either specific or “random”, depending on the purpose of the product. 
However, just as with genomics and proteomics, the actual process is much more complex than this 
explanation lets on [23, 202, 204].   
The endogenous peptide content, the endopeptidome, of CSF originates to an unknown degree from 
processes in and around the CNS, but also from other parts of the body, as large portions of the CSF 
content is a filtrate passed over the BBB [93]. In general, a large number of intra- and extracellular 
processes are involved in protein degradation for various purposes, being it simply for removal of “waste 
proteins/peptides” or recycling of amino acids, for generating bioactive peptides or for various immune-
system functions [205, 206]. The remains of such ongoing processes in the CNS can be detected in CSF 
and are, in some cases, possible to use as biomarkers to determine the state of the machinery upstream, 
the most prominent example being Aβ1-42 or P-tau 175-190 [93] (Hansson et al., manuscript submitted). 
Finally, the fact that there is a large number of endogenous peptides present in CSF [207], which 
functions are largely unknown, can be a complicating phenomenon in proteomics. Large numbers of 
peptides such as hormones, neurotransmitters and neuromodulators are bioactive in themselves and 
degrading them through proteolysis and simply employing the remainder to infer information on the 
originally expressed protein is to lose information on the studied system [23]. Proteomics and 
peptidomics are compatible areas of study and should be combined to generate the maximum amount 
of information. 
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 Aim 
2.1. General aims 
The aim with this thesis is to investigate the endogenous peptides present in human cerebrospinal fluid, 
the CSF endopeptidome, and to evaluate their usefulness in the diagnosis of neurodegenerative diseases, 
primarily Alzheimer’s disease.  
2.2. Specific aims 
I. Develop and/or optimise methods for peptide isolation, peptide separation and peptidome 
deconvolution, mass spectrometric analysis and identification of endogenous peptides from 
raw ms/ms-data. 
II. Identify and evaluate endogenous peptide biomarker candidates through targeted mass 
spectrometric analysis  
III. Develop online liquid chromatography-based sample preparation protocols for rapid isolation 
of endogenous peptide biomarkers for robust clinical routine analysis by mass spectrometry   
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 Methods 
The main body of work performed in the studies included in this thesis aimed at developing and/or 
optimising methods and protocols for various purposes in the study of endogenous peptides in human 
CSF. The protocol for discovery peptidomics here developed and employed is superficially similar to a 
standard shotgun proteomics protocol. There are however fundamental differences; in peptidomics, as 
compared to proteomics, analytes (peptides) are not generated but acquired since they are already 
present in the sample, and most importantly analytes do not directly infer information in a hierarchical 
manner [23]. This means that endogenous peptides are primarily studied as stand-alone entities, which 
can potentially be employed to infer information on the system in an indirect manner. 
3.1. Sample pre-treatment 
Biological samples nearly always constitute a complex mixture of components wherein the analytes of 
interest make up a smaller or larger fraction of the whole. Once the sample has been extracted, it is 
therefore commonplace to perform some degree of chemical or mechanical treatment in order to either 
remove components whose presence would otherwise be detrimental to analysis and/or to make the 
sought-after analytes more readily available for analysis 
The mass spectrometric instrument employed in most of the work is sensitive both in the sense of being 
able to detect low-abundant analytes but also in being easily interfered with. Hence, a large section of 
the components of the original CSF sample had to be degraded and/or removed to improve analysis 
quality and robustness, or simply to make sure the HPLC and/or MS would not clog or break down. 
3.1.1. Protein denaturation 
A protocol for selective acquisition of endogenous peptides developed by Mikko Höltta et al. (2012) 
was adapted to some degree from a standard proteomics protocol. This means that the protocol included 
both protein aggregate-disruption through employment of a chaotrope as well as reduction and 
alkylation of bridges to avoid spontaneous folding and forming of novel protein aggregates – meant to 
prepare the sample proteins for proteolytic degradation [208]. Over the course of the studies carried out 
here, the protocol was altered to some extent, primarily to accommodate a larger volume of CSF per 
sample but also to re-adjust the active concentration of reagents used for protein denaturation. 
The chemical disruption of protein aggregates employed in the protocols used here is performed in two 
steps; the first is meant to break up protein quaternary, tertiary and, to some degree, also secondary 
structures. To this end is a detergent or  chaotropic agent (chaotrope), for example sodium dodecyl 
sulphate (SDS), urea or various guanidinium salts commonly employed; here was primarily guanidinium 
hydrochloride (GdnHCl) used [209]. The chaotrope acts through altering protein-protein and/or protein-
water interaction by causing either water molecules or the proteins to rearrange around the chaotrope, 
and making non-covalent interactions (mainly van der Waals interactions) between proteins less 
energetically favourable [209-211]. Employing a sufficiently high concentration of chaotrope thereby 
results in both aggregate disruption and some degree of protein unfolding – leaving only covalent 
interactions [209, 212].  
The second protein structure-disruption step is meant to unfold the proteins completely and to 
permanently keep them from re-folding by breaking cysteine-cysteine di-sulphide bridges [213]. 
Cysteine residues present a reactive sulfhydryl group which readily oxidises other sulfhydryl group 
resulting in intra- and inter-protein covalent disulphide bridges between cysteines [214]. The disulphide 
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bridges need to be broken to allow for protein unfolding. However, since the formation of di-sulphide 
bridges are energetically favourable the sulfhydryl groups also need to be made permanently non-
reactive in order to avoid spontaneous formation of new bridges. As usual there are many ways to 
approach the issue, but in general disulphide bridges are initially broken through the action of a reducing 
agent [213, 215-217] (see figure 1), such as dithiothreitol (DTT), 2-mercaptoethanol (BME) or tris (2-
carboxyethyl) phosphine hydrochloride (TCEP) – just to mention a few.  
 
Figure 1: Reduction of an arbitrary disulphide linkage through two-step thiol-disulphide exchange induced by DTT  
The sulfhydryls are subsequently rendered non-reactive (“are capped”), commonly through covalent 
binding of an alkyl group to the free sulfhydryl group; a process known as alkylation [218, 219]. In this 
case the alkylating reagent was iodoacetamide (IAA), which causes the non-reversible addition of a 
carbamidomethyl group to the cysteine sulphur residue under alkaline conditions (see figure 2).  
 
Figure 2: Carbamidomethylation of a cysteine sulfhydryl group at alkaline pH with IAA  
The expected/desired effect of these treatment-steps is more or less to completely unfolded proteins. 
The side effects involve the alteration of the expected mass of each cysteine during peptide 
identification. The alteration of mass corresponding to carbamidomethylation is an addition of 
approximately 58 Da to cysteines, which must be included as a static modification or result in erroneous 
peptide identification.   
In proteomics these preparation steps are performed to improve the enzymatic digestion of proteins in 
to peptides prior to analysis. By unfolding the proteins, more cleavage sites are made available and a 
more complete digestion is achieved. In peptidomics on the other hand the hypothesis was that the same 
treatment would result in less endogenous peptides being tied up in aggregates and allow for better 
peptide recovery after using a molecular weight cut-off (MWCO) filter. However, trials in which 
reduction and alkylation were left out of the protocol showed little effect on the number of identified 
endogenous peptides (data not shown). Since the trials were non-quantitative it was not possible to tell 
if avoiding these steps actually caused losses, general or in specific peptide species, so the practice of 
reducing and alkylating was mostly retained. In contrast, leaving out aggregate disruption by means of 
chaotropic treatment did impact identification negatively. A possible clue to the cause of this was 
19 
 
observed during an experiment with turbulent flow chromatography (see below) where the non-treated 
samples caused immediate blocking of the separation column. 
3.2. Molecular weight cut-off ultrafiltration 
In terms of complex biological constituents, CSF primarily contains a small number of highly abundant 
proteins, e.g. albumin and immunoglobulins, as well as somewhere between 2000-3000 less abundant 
protein species [9, 10, 91, 220-224]. The endogenous peptides we sought to study most likely constitute 
only a small, albeit highly diverse, fraction of the total mass [90, 207, 225-228]. Since a peptidomics 
protocol seeks to isolate the peptides, one of the first steps is to separate the small fraction of peptides 
from the vast bulk of proteins. 
 
Figure 3: Visualisation of the principles of molecular weight cut-off filtration, accurate to a given value of “accurate”. 
Several techniques have been applied for the purpose of selectively isolating endogenous peptides from 
proteins, or rather, to isolate peptides and/or proteins below a certain mass-range from those above (there 
is of course a span where the masses of large peptides and small proteins overlap, but intricacies of this 
type are beyond the scope of this thesis). The primary approaches for isolating small endogenous 
peptides are protein depletion, size exclusion chromatography (SEC) [229] and MWCO ultrafiltration 
[24]. There have also been relatively recent reports of protocols for separating peptides as small as 500 
Da using gel electrophoresis techniques [230] which might be of future interest.  
There are advantages and disadvantages associated with each method but a limited amount of time to 
investigate and evaluate each one. Eventually, we chose to primarily focus on and optimise an MWCO-
based separation protocol. The choice was made partly because of experience from earlier in house 
studies by Mikko Höltta and colleagues, where the efficacy of various MWCO filters for the purpose of 
peptide separation was tested and subsequently employed [226, 228, 231, 232]. Further, there is a 
relatively large amount of data supporting the functionality of MWCO for peptide isolation in complex 
biological samples [222, 233-237]. Finally, the MWCO filters are (typically) single-use cartridges, 
available in a range of filter sizes and sample loading volumes, which allows for straightforward up- or 
down-scaling and general ease-of-use. The Amicon® ultracentrifugal filters we eventually selected 
employed a membrane of regenerated cellulose, and a collection tube of polypropylene, making for a 
relatively inert system with small analyte losses and ditto risk of contamination.   
The basic mode of operation of the MWCO filters relies on assisted passage of molecules below a certain 
size/mass by means of centrifugation. In practice, one adds sample on top of the filter and spins it to 
induce several thousand times the natural gravity, causing the whole sample to move along the vertical 
axis of the cartridge and into the membrane. The membrane supposedly retains everything larger than 
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the specified pore size (the “molecular weight ut-off”-point) and thus produces a filtrate containing only 
sub-MWCO molecules.  
In the study performed by Höltta et al. (2012) it was shown that the greatest number of identified 
endogenous peptides resulted from employing a MWCO filter with a cut-off at 30 kDa, which is 
substantially greater than the mean mass of the peptides (both expected and subsequently identified). 
Since our goal was to identify as many peptides as possible, the 30 kDa filters were chosen also for our 
studies. However; since the size of the pores suggested that a number of small proteins could potentially 
be included in the filtrate we investigated the filtered sample on an SDS-PAGE gel – but could find no 
trace of any protein or peptide larger than 6 kDa (see figure 16). The cause to this is difficult to speculate 
on, but it suggests that simply relying on the specified pore size of the MWCO filter may result in errors 
and that the method requires re-evaluation if one seeks to study another mass-range.    
3.3. Solid phase extraction: principles 
Biological samples commonly contain a complex mixture of molecules. The sought after analytes, in 
this case primarily endogenous peptides, are mixed with other CSF constituents such as salts and cell 
debris as well as proteins, often referred to as interfering matrix components [238]. Since the presence 
of the interfering components may negatively impact the MS analysis it is crucial to remove as much as 
possible without losing analytes of interest. Proteins can be removed by various means, such as MWCO-
filtration as described in the previous section. However, after the filtration the sample still contains, 
beyond the endogenous peptides, small organic molecules (e.g., lipids) as well as non-organic salts and 
other matrix components, which requires further sample treatment to be removed.  
Two approaches for selective exclusion of unwanted molecules was evaluated during the course of this 
thesis work; solid phase extraction (SPE) and turbulent flow chromatography (TFC). Since TFC is also 
employed to separate small endogenous peptides from the remaining components of CSF, it is described 
in a separate section below (see section 2.5.2.). SPE takes advantage of the physiochemical properties 
of proteins/peptides to selectively retain them, a filter that includes or excludes based on other properties 
than size/weight [238].   
A variety of formats are available for the purpose of SPE, as well as a number of properties for retention 
[239]. In the current case, disposable cartridges filled with a siliceous packing material coated with 
hydrocarbon chains with an 18-carbon long backbone (C18) which retain molecules based on 
hydrophobic interaction were employed. The properties of SPE makes it ideal since that components of 
CSF span a wide range between the extremes of hydrophilicity/hydrophobicity. Salts are generally 
highly hydrophilic and cell debris highly hydrophobic, while proteins and peptides commonly occupy a 
more moderate range on this scale, which can be used to selectively capture them [240].     
The employed SPE system uses a crude form of reverse phase chromatographic separation; the peptides 
and proteins as well as cellular debris are retained on the column because their hydrophobic interaction 
with the stationary phase is stronger than that to the mobile phase, while salts and other small molecules 
wash over. In the subsequent step a secondary mobile phase with a suitable concentration of organic 
component is washed over the cartridge and the proteins/peptides are eluted into the new mobile phase. 
By employing an eluting mobile phase that contains a sufficiently high concentration of organic 
component to elute peptides, but not high enough to elute cellular debris, the SPE approach allows for 
removal of a large section of unwanted matrix components from the sample. 
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3.4. Losses and contaminants 
It must be noted that sample preparation in general also means analyte losses. Since the analytes in 
question, i.e., peptides, come with such a broad range of physiochemical properties, each preparation 
step inevitably means losing some of them [186, 241-243]. For instance, transferring the sample from 
one container to another means losing peptides to the surface of the first container, to the surface of the 
pipet-tip and then to the surface of the second container.     
Secondly, the risk of introducing unwanted components into the sample was an ever-present issue, and 
especially prominent in the lengthier protocols. Since the MS can detect excessively small quantities of 
any analyte, there did not need to be large or even noticeable accidents to reduce a sample to a literal 
cess-pool of unwanted molecules in the context of advanced biochemical analysis. What constitutes a 
contaminant is highly dependent on the studied analyte. The settings of the MS determine what is 
detectable and, if peptides is the target, anything that resembles a peptide in terms of physiochemical 
properties can be a contaminant – including off course peptides [244]. In the case of peptidomics and 
proteomics the most commonly occurring contaminants are synthetic carbohydrate polymers, 
particularly, in the view of this researcher, polyethylene glycol (PEG) [244].   
Hence, while sample preparation is essential in order to detect peptides, the more extensive the sample 
preparation was, the higher the risk of introducing various contaminants and the risk of losing peptides. 
For instance, a balance between the optimal concentration of a chaotrope for breaking protein aggregates 
and the maximum concentration that causes polymer leaching in subsequent steps was painfully 
determined.   
3.5. Reversed-phase liquid chromatography 
Chromatographic separation of the sample constituents is a generally useful practice, especially in bio 
analysis where sample complexity is usually high. Including an HPLC step prior to MS analysis is meant 
to limit the amount of analyte species which enters the instrument at any given time. Depending on the 
analyte-composition of a sample, different modes of separation are employed. For the purpose of 
temporally spacing out biopolymers (such as peptides), which physiochemical properties are as varied 
as they are complex, in solutions containing hundreds, thousands or even tens of thousands different 
analyte species it is important to understand that there is no perfect choice in separation method (at least 
not at this time). That said; various different approaches have proven highly useful in the 
chromatographic separation of biopolymers prior to analysis, such as ion exchange chromatography 
(IEC), possible none more so than the method of employing hydrophobic interaction between the 
column stationary phase and the analytes, known as reversed-phase liquid chromatography (RPLC) 
[245, 246].   
The RPLC principle of action is to retain peptides based on their higher affinity for the non-polar 
stationary phase during sample loading with a mobile phase of low (a few %) organic content [247, 
248]. By subsequently gradually increasing the hydrophobicity of the mobile phase by increasing the 
concentration of organic component, peptides again shift their affinity but now from stationary to mobile 
phase. Since hydrophobicity is an inherent peptide property dependent both on constituent amino acids 
as well as their relative position and various external factors, such as pH and temperature [249-251], 
RPLC is a highly diverse, dynamic and effective means of peptide separation [252].  
In the context it also seems relevant to note the separation technique known as HILIC (hydrophilic 
interaction liquid chromatography) first described by Alpert (1990) [253], which is in practice, if not in 
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definition, a form of RPLC where peptide retention is based on hydrophilic interaction and elution is 
performed by decreasing the hydrophobic component [254].   
The ability to control the rate of analytes eluting from the column by means of mobile phase gradient 
allows RPLC to be one of the most, if not THE most, highly resolving chromatographic separation 
techniques currently available. Implemented on a high- or ultra-high performing liquid chromatography 
system, RP separation can allow for a system with unsurpassable peak capacity [255], making it a highly 
useful, particularly for discovery proteomics. 
In the current work RPLC was applied both for on-line purposes (i.e., coupled to an analysis instrument, 
such as an MS) for straight forward separation of CSF peptides, but also for off-line sample clean-up 
purposes as well as for pre-fractionation to further deconvolute the sample prior to MS analysis. 
3.5.1. Sample pre-fractionation 
The study in paper I aimed at deep exploration of the CSF endopeptidome, with the explicit intent of 
discovering as many endogenous peptides as possible. Various steps were taken to achieve this goal but 
the most prominent was the introduction of off-line (“not connected to any analytical instrument”) 
chromatographic sample fractionation of the isolated endogenous peptides following MWCO filtration. 
The most direct advantage of this procedure is to reduce the complexity of the sample, decreasing the 
chances of peptide co-elution from the LC-column during sample separation, resulting in improved peak 
capacity of the LC-MS/MS system and potentially allowing for a higher number of identified peptides 
[256, 257]. 
Further and parallel to the reduction of sample complexity, pre-fractionation importantly allowed for 
the use of a six-fold increase of initial CSF volume, from 250 µL to 1.5 mL. Since the nano-LC trap 
and/or separation columns determines how much sample material can be analysed in a single LC-
MS/MS run, high sample complexity means that the total analyte mass is “spread out” over a large 
number of analyte species [258, 259]. By reducing the total number of analyte species in a single fraction 
and simultaneously increasing the total amount of those analytes still present, detection of individual 
analytes was improved, particularly benefitting detection of low-abundant ditto [229, 256-258]. 
The obvious disadvantage of fractionation is an increase in the number of analysis runs and thereby a 
dramatically prolonged total analysis time. To tackle this problem, a strategy for reducing the total 
number of fractions without causing analyte losses or reintroduce a high degree of complexity was 
implemented. The solution was to combine fractions of peptides eluting sufficiently far apart, i.e., with 
sufficiently large difference in eluting hydrophobic mobile gradient component, in a so called 
“concatenation scheme”. The approach allows analyses of several fractions per LC-MS/MS run, saving 
time by avoiding for instance sample loading time and column cleaning, and results in a number of 
“peptide islands” being analysed; peptides from one fraction are eluted and analysed over a period, 
followed by a pause in peptide elution until the peptides from the next fraction start eluting.  
However, the fractionation/concatenation approach can be made more advanced, and the peak-capacity 
can be further improved, by implementing different LC-separation properties between the off-line and 
on-line LC steps [260]. In the current case we chose to perform the separation steps over two RPLC 
columns based on hydrophobic interaction but at two distinct LC-gradient pHs; first off-line at pH 9 
followed by on-line at pH 3. Since peptide retention properties can be affected by local pH, this strategy 
meant that the peptides deposited in one particular fraction at a high pH would slightly alter their 
retention in the next separation step (on-line at low pH) and elute at comparatively  different gradient 
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point (compared to the off-line separation)[251, 261]. By ensuring, that peptides eluted relatively far 
apart, but also more or less continuously, high peak-capacity and efficient analysis can be achieved [251, 
261-263]. 
3.5.2.  Turbulent flow chromatography 
Mass spectrometric instruments for highly sensitive, specific and rapid proteomic analysis is becoming 
more and more prevalent, and is also available at evermore reasonable prices. The current goal for 
several manufacturers seems to be to develop “plug-and-play”-type instruments, which requires little in 
the ways of operation experience to yield results [264-266]. The advantages of employing such MS 
systems in routine clinical analysis is becoming clearer as more and more protein and peptide biomarkers 
emerge [5, 12, 267-270]. In paper II we investigated a chromatographic setup for peptidomics meant to 
bridge the gap between sample pre-treatment and MS-analysis by providing both selective peptide 
isolation and sample clean-up in a single chromatographic step. The approach is known as TFC and is 
based around a separation column built to handle comparatively high flow rates whilst otherwise 
retaining the same functions as a standard reverse phase column based on hydrophobic interaction [271, 
272].  
In essence, the TFC method employs the physical characteristic that smaller/lighter molecules are more 
prominently affected by current flow than are larger ditto [273]. Radial motion in tube flow is greater 
for smaller molecules, resulting in them taking a more indirect (more winding) path through the 
chromatographic separation column, increasing the chances of the molecule coming in contact with, and 
being retained on the stationary phase [274, 275]. 
 
Figure 4: Flow-profile evolution in a closed pipe in response to increasing flow-rate. From left to right: low or laminar flow 
results in a parabolic flow-profile with the highest relative velocity in the centre of the tube; as the flow-rate increases the 
comparatively rough inner surface of the tube causes eddies to form and    
Briefly, the general protocol for TFC-based isolation of endogenous peptides is carried out as follows. 
After extraction through lumbar puncture, CSF is briefly pre-treated to denature protein aggregates and 
subsequently diluted and loaded in the normal-flow liquid chromatograph. The chromatographic 
instrument (liquid chromatography, LC) employs a high flow-rate (0.5-2.0 mL/min) during sample 
loading to induce turbulence in the mobile phase and ensure sample liquid bulk turn-over, the flow-rate 
is then reduced (~0.1 mL/min) to minimise the eluting volume. No particular mobile phase gradient is 
employed; the sample is loaded in a mobile phase containing a low concentration of organic solvent 
(e.g., 2-3% acetonitrile) and eluted by a relatively brief pulse (~1-2 min) with increased ditto (50-80% 
acetonitrile).    
In short, TFC is meant to allow for selective retention and isolation of small analytes, e.g., peptides, 
while larger molecules, e.g., proteins, washes over during sample loading. With some alterations to the 
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LC-setup described in paper II, the TFC could be connected to a suitable MS for rapid targeted analysis, 
for instance a triple quadrupole, in a way similar to that described by Chassaing et al. in 2000 [276]. 
Employing TFC in this manner could allow for a highly automated endogenous peptide biomarker assay 
based on chromatographic sample preparation and MS-analysis.  
3.6. Mass spectrometry 
In essence, MS means exposing the mass analyser to suitable analytes (ions in gas phase), accelerating 
the analytes over magnetic or electric fields into a detector and studying the resulting collision to yield 
a mass-to-charge (m/z) value of the analyte [277]. Albeit the concept is simple the implication is that, 
with suitable equipment and knowledge, the contents of any sample can be determined, considered 
useful by some.  
The general applicability of MS technology has led to branching and specialisation of instruments for 
the study of a great variety of analytes in an equally varied set of environments, from the security 
terminal at the airport to the surface of Mars [278-281]. In the fields of life science, developments in 
MS technology have focused on dealing with the unique set of problems involved in studying samples 
containing tens of thousands of large, delicate and intricate molecular species [15]. Further, biological 
sample materials - whether it being tissue, plasma, CSF, faecal matter etc – often constitute a complex 
array of molecules, known as the sample matrix [282-285]. Most bio analysts focus on a subset of said 
molecules, for instance lipids, metabolites or proteins. Even so, after isolating the preferred subset of 
analytes, the samples are still commonly highly intricate and further extensive sample preparation is 
required before analysis. Finally, the size and physiochemical characteristics of biological molecules 
often means that they do not readily acquire the features required to be detectable in an MS, demanding 
specialisation of the instrument for this purpose [17, 22, 282].  
In practice, a mass spectrometer consists of three distinct parts; the ion source, the mass analyser and 
the detector. The ion source constitutes the interface wherein sample analytes acquire a charge, are 
ionised, and are volatilised (transferred into gas phase) thereby allowing for detection by the mass 
analyser [286]. There are a number of approaches for the purpose of turning atoms and molecules into 
ions and the method employed is chosen based on the nature of the sample [287]. Biological molecules 
tend to be large and easily disrupted and therefore demanding of careful and deliberate handling [24, 
288]. 
Next after the ion source is the mass analyser which determines the area of application of the instrument. 
Apparent from the name, this is where the ions are “measured”, and data collected and subsequently 
exported in the form of m/z [289]. As with the mode of ionisation there is several distinctly different 
mass analysers as well as a number of ways in combining them into so called hybrid instruments [289, 
290].  
The final stage of the MS is the ion detector which adds a relative intensity, or relative abundance, value 
to the m/z of each ion species through conversion of the energy in incoming ions into a measurable 
signal [291, 292]. The detector is essential to the MS instrument and yet the progress in detector 
development has not kept the same pace as those made in the areas of ion sources and mass analysers. 
According to Koppenaal and colleagues, writers of one of the few reviews on the subject, this is because 
of a general lack of appreciation for the complexities involved in choosing an ideal detector as well as 
a low frequency in specifying what detector is in a particular trial [291]. The fact however, seems to be 
that because of slow development and lack of differentiation the consumer has not got so many options. 
One expects that the instrument one has just bought for a few million SEK is equipped with a detector 
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suitable for the purpose specified, i.e., uniformly detect ions between 100-100 000 m/z, without losing 
mass response.  
3.6.1. Ionisation 
Mass spectrometry is based around the more or less predictable behaviour of charged particles in space 
for assigning specific m/z values to said particles [293]. This means that the instrument is “blind” to 
non-ionised particles and hence that ionisation of the target analyte is central. Various methods for 
ionisation have emerged and are employed depending on phase of the sample (gas, liquid or solid) as 
well as the physiochemical properties of the studied analytes. The MS may have a number of limitations 
regarding, for instance, analyte mass range but in theory, the mass analyser is able to detect any charged 
particle that enters it. However, the larger and more complex a molecule is the more difficult it is to 
ionise and still keep it intact [17].  
Early attempts at analysing biological samples were hindered by the difficulties in generating sufficient 
amounts of ions without destroying the analytes [17, 22, 294]. Ionisation of any molecule/atom occurs 
as a result of energy transfer to the molecule in question, in the case of large molecules a localised energy 
surge may cause the molecule to disintegrate [17], and although ms/ms is based around breaking apart 
(fragmenting) analytes, it has to occur in an orderly manner. For the purpose of studying complex sample 
materials (i.e., most biological extracts) of large and similarly complex molecules (primarily proteins 
and peptides), a number of techniques employing so called soft ionisation were developed [16, 17, 21].  
“Soft ionisation” in practice means indirect energy transfer and developments of the technique have 
revolutionised the field of mass spectrometric analysis of bio molecules. Two prominent examples of 
soft ionisation known as matrix assisted laser-desorption ionisation (MALDI) and electrospray 
ionisation (ESI), both were developed at the end of the 1980s. In MALDI the sample is transferred to 
µL wells or “spots” on a target plate and coated with an adsorbing substance (matrix) [295]. The target 
plate is placed inside the MS under vacuum and the spots are shot at with a UV laser, the effect is 
complex but results in both the matrix absorbing and transferring incoming energy to the analytes in the 
sample as well as the sample being “exploded” out of the surface  [295, 296].  
In comparison, ESI was developed to ionise analytes continuously as they emerge from an LC-capillary, 
enabling online chromatographic sample separation and mass spectrometric analysis of large 
biomolecules [16, 17]. As the flow of liquid sample reaches the end of the LC capillary it enters a 
stainless-steel needle with the nozzle divided by a few cm from the MS-inlet (see figure 5). An electric 
field in the kilovolt-range is maintained between needle and inlet, resulting in charges being deposited 
unto the liquid sample droplets as they exit the nozzle [18].  
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Figure 5: Schematic representation of an electrospray ionisation (ESI) source 
As the droplets traverse the interface between nozzle and inlet, the volatile liquid evaporates, 
concentrating the deposited charges until the charge density is too high and causes the droplet to bursts 
into daughter droplets, a process known as “Coulomb explosion” [17, 18]. This continues until the liquid 
has evaporated and all that remains (in theory) are single molecules retaining some of the initial charge, 
i.e., ions in gas phase [17]. 
3.6.2. Mass analysis 
The ways to determine the mass of a particle have been explored extensively resulting in a relatively 
large variety of different approaches for this purpose. A large number of factors affect what type of 
sample can be studied by one particular MS (and even more if the instrument is coupled to a 
chromatographic system). However, the nature of the mass analyser ultimately determines what can be 
“seen” in a given sample material as well as the quality of the generated data. The fundamental factors 
of MS analysis, e.g., scan speed, mass range, sensitivity, selectivity, mass accuracy and instrument size 
affect one another in such a manner that no instrument yet combines the best of all. The complex nature 
of biological samples has therefore resulted in many life science laboratories employing several MS 
systems for various types of analysis of a single type of material. Below are described the two mass 
analysers primarily employed in this thesis work; the quadrupole and the orbitrap.          
3.6.2.1. Quadrupole 
The basic quadrupole consists of four parallel conductive rods placed, as the name suggests, opposite 
one another creating a central chamber between in- and outlet (see figure 6). The instrument employs a 
complicated electric field scheme for influencing ions entering the chamber, which allows for two 
distinct modes of operation: mass filter or ion trap [297-299].  
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Figure 6: Schematic representation of a quadrupole ion trap 
Ions entering the quadrupole are exposed to the effect of a combined electric fields resulting from both 
a direct current (DC) and an alternating current (AC) induced by a radio frequency (RF) field [298]. The 
DC field is weak compared to the RF field and its function is primarily as a stabiliser, each rod-pair is 
consistently either attracting or repelling ions and focusing them in the centre of the quadrupole 
chamber. The stronger RF field switches polarity periodically, meaning that each rod-pair becomes 
alternatingly attractive or repelling causing the ion trajectory to have its own amplitude in both the x 
and y planes, the RF field thus functions as a destabiliser. Ions that exit the trap reach an external detector 
and produces a signal. Since individual peptide species are ejected by a unique RF amplitude 
corresponding to their m/z-ratio, by linearly increasing the amplitude and noting at what point the signal 
is detected, a specific m/z-ratio and intensity can be given to each analyte, resulting in a mass spectrum 
[297]. When operating as a mass filter the quadrupole is set to a specific RF amplitude corresponding 
to a certain m/z-window, the result is that only ions within said m/z-range will have a stable linear 
trajectory and pass through the filter [300-302].    
A common setup is the triple quadrupole (QQQ) MS, i.e., a series of three sequential quadrupoles each 
with particular tasks which together allows for rapid, robust and sensitive quantitation [190, 303, 304]. 
The first quadrupole (Q1) filters for a targeted precursor by implementing a narrow mass window, the 
second quadrupole (Q2) is employed as a collision cell to fragment the precursor into product ions and 
the last quadrupole (Q3) functions as a second mass filter, this time for one or several product ions (albeit 
only a single fragment per scan) [299, 301, 304, 305]. The Q2, here employed as an ion trap and collision 
chamber, uses a technique called “momentum-dissipating collisions” (a.k.a. ion cooling) where analyte 
ions caught in the potential well of the trap are confined to the centre of the quadrupole by low-energy 
collisions with helium atoms at low pressure [297]. Subsequently the analytes are briefly (~10 ms) 
excited along the z-axis by irradiation at several frequencies simultaneously (multiple-frequency 
irradiation, or MFI) causing fragmentation of the precursor by multiple collisions with helium atoms in 
a process known as collision induced dissociation (CID) [306-309]. The product ions are subsequently 
ejected into the Q3 where the second mass filter selectively remove all ion species outside the specified 
m/z-window, allowing only a select set of product ions to reach the detector. 
The quadrupole and the triple quadrupole have both kept and found new niches in the analytical sphere, 
are commonly employed in hybrid instruments, and are much appreciated for their speed, ion storage 
capacity and, in QQQ-mode, highly sensitive and well adapted for absolute quantitation [310-313]. In 
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the work performed here the quadrupole was employed in conjunction with an orbitrap mass analyser 
(see below). Further, pilot trials in developing a rapid biomarker assay on a triple quadrupole were 
initiated but put on ice due to longer-than-expected method optimisation.   
3.6.2.2. Orbitrap 
The aforementioned complexity of biological sample materials will not be discussed again, except for 
the fact that the phenomenon has required and resulted in the development of some extraordinary pieces 
of bioanalytical technology. The orbitrap mass analyser, introduced for commercial use in the early 20th 
century by Alexander Makarov and colleagues [314, 315], is an excellent example; combining 
previously incompatible properties of high resolution, mass accuracy, throughput and broad dynamic 
range [316, 317]. 
The  mass analyser system is based on the rotational behaviour of ions around an electrode in an 
electrostatic field (see figure 7) [314]. Ions are injected into the trap at a set energy level and only ions 
with a suitable tangential velocity will take up a stable orbit around the central electrode. The behaviour 
is in many ways similar to that of planetary bodies moving around a central star; too low velocity and 
the orbit decays, making the body fall into the gravitational well of the star, too high velocity and the 
body bounces out into space (i.e., the inner wall of the trap).  
 
Figure 7: Schematic representation of an orbitrap mass analyser, including the external C-trap. Reprinted with permission 
from Thermo Scientific, copyright 2018. 
The initial tangential velocity and mass determines radial distance of the ion cloud of each analyte 
species. This characteristic could be employed to determine m/z values. However, since the radial 
distance is affected by initial velocity this analysis approach would be sensitive to variations in the 
injection energy from the C-trap, resulting in loss of accuracy [317]. Instead the orbitrap employs the 
phenomenon that the ions orbiting the electrode also moves back and forth, oscillates, along the 
electrode (z-axis) in a manner dependent only of their m/z-ratio [314]. Because of the harmonic 
oscillation pattern being independent from rotational and radial velocity, except for the initial 
requirement of taking up a stable orbit, it can be exploited to determine ion mass with a very high 
accuracy (>0.1 ppm) [317-319].  
Interestingly, the orbitrap is by itself not a particularly well-functioning instrument. For the purpose of 
continuous analysis of complex samples, in the least it requires an external trap for injecting defined 
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quantity of analyte ions (the C-trap) as well as some type of collision chamber for product ion 
fragmentation [265]. Other sought after attributes, not provided by a lonesome orbitrap, is sensitive ion 
detection and precursor selection [316]. These and other issues were first addressed by simply adding a 
linear ion trap equipped with a quadrupole ion trap and a CID collision cell upstream of the orbitrap 
[290]. The LTQ Orbitrap is an example of a hybrid mass spectrometer, intended to combine the best of 
two worlds; in this case the high resolution and high mass accuracy of the orbitrap and the high 
sensitivity and ms/ms capability of a linear mass analyser. Since the instruments employed for the vast 
majority of data collection in this thesis were orbitrap hybrid instruments, this concept will be described 
in a separate section.  
Importantly, the orbitrap mass analyser, combined with the HCD cell (explained in further detail below) 
as well as a few other features, such as the automatic gain control (AGC), which allows for rapid 
estimation of the ion population size, has improved the ability to perform relative quantitation through 
multiplexed isobaric labelling [316].     
3.6.3. Ion fragmentation methods 
The concept of tandem mass spectrometry involves a primary analysis step in which the incoming ions 
are detected in the mass analyser and an m/z value is added to each species. For large molecules, such 
as peptides and proteins, in complex sample matrices, this first step simply does not sufficient determine 
the exact nature of the molecule – i.e., the amino acid sequence. Hence, a secondary analysis step, an 
ms/ms, is performed. From the ion stream entering the instrument one selected ion species, a precursor, 
is filtered to be fragmented, or disassociated, and subsequently having the resulting product ions 
analysed. The product ion information, the ms/ms data, is eventually employed to infer information on 
the precursor – this is the essence of tandem mass spectrometry. 
There are several modes of fragmentation and the method chosen has a significant impact on the 
resulting data. In principle the protein/peptide backbone can be broken to primarily generate three 
distinct pairs of ions: a-x, b-y and c-z (see figure 8). The method of fragmentation determines what type 
of product ion pair is generated as well as to what extent a precursor is fragmented [320]. Below are the 
three approaches used for generating product ions for ms/ms-analysis in the works of this thesis 
described.  
 
Figure 8: Visualisation of the peptide fragmentation sites along the amide bond backbone, also shown are the three possible 
ion pairs: a-x, b-y and c-z  
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3.6.3.1. Collision-induced dissociation 
CID and HCD are similar techniques based on, as the names suggest, causing the precursors to break 
apart through collisions – in both cases with an inert gas, e.g., nitrogen/helium/argon. In both cases (and 
despite the “higher energy” in HCD) the precursor is typically fragmented through multiple collisions 
at energy levels between 1-100 eV over a brief period of time [308, 309]. The dissociation of the peptide 
backbone is not caused by the physical collisions themselves but rather the atomic/molecular vibrations 
resulting from absorption of momentum energy [308, 309]. The vibrational energy causes an amide 
bond-break, resulting primarily in complementary b- and y-ions.     
The main difference between CID (performed in a linear ion trap) and HCD results from where and 
under what conditions the collisions are carried out. CID is performed within the confines of an ion trap 
and the trap thus also must act a collision cell. In contrast, HCD is performed in a dedicated collision 
cell, usually a higher-level multipole [321]. The dual requirements of the ion trap primarily results in an 
upper limit to the collision-energy employed in CID, this because a too high energy will cause 
randomised ejection of ions of all sizes due to instability triggered by transference of momentum [309, 
321, 322]. This means that CID has a lower mass cut-off point and cannot detect most immonium ions 
nor be employed for detecting reporter ions from isobaric labelling reagents such as TMT. HCD, on the 
other hand, has no lower cut-off mass (except most Orbitrap instruments anyway has a lower limit of 50 
Da – but for other reasons) and allows both for improved identification of PTMs as well as reporter ions 
[321]. Further the higher energy levels allow for a greater degree of fragmentation; that is, HCD 
generates a larger variety of product ions and thereby higher quality ms/ms data [323]. 
Even though HCD is generally slower than HCD, the speed of fragmentation makes both methods ideal 
for LC-MS/MS type experiments where analysis time per peptide is preferably low. Finally, regardless 
of individual differences both methods have proven instrumental in proteomics and peptidomics. 
Primarily because the collisional approach is highly efficient in breaking the amide bond-backbone of 
small to relatively large (<6000 Da) protonated peptides in a quite predictive manner [309, 324-326].  
3.6.3.2. Electron transfer dissociation 
Electron transfer dissociation (ETD) is a relatively novel method for amide-bond dissociation, 
discovered to some degree by chance4 in the late 90s [327]. Briefly, protein/peptide dissociation is 
achieved through a three-step process; 1) radical anions are generated by a negative ionisation of 
(usually) large aromatic hydrocarbons, 2) an electron is transferred from the radical anion to the 
protonated precursor ion through interaction in the ion trap and, 3) the presence of an odd electron on 
the otherwise positively charged peptide/protein causes destabilisation and a break occurs along the 
peptide backbone, generating c- and z-ions as a consequence [328, 329]. Importantly, ETD does not 
seem to be affected in particular by the size of the precursor but is instead limited by the charge state of 
the precursor in the generation of product ion pairs [330]. Further, this mode of fragmentation is specific 
for the peptide backbone and is thus suitable for PTM analysis since ETD does not result in random 
“knock-outs” of covalent amino acid modification, as is common in CID [321, 330].  
                                                     
4 According to the authors they were attempting to combine neutralisation-reionisation with surface-induced dissociation to 
generate peptide ions for MS (as one does), but found that although the intended approach did not cause any cleavage, the 
neutralisation reaction with low-energy electrons itself did results in randomised protein dissociation along the amide bond-
backbone [327] Zubarev, R. A., Kelleher, N. L., McLafferty, F. W., Electron capture dissociation of multiply charged protein 
cations. A nonergodic process. Journal of the American Chemical Society 1998, 120, 3265-3266.. 
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The mechanism of ETD is fundamentally different from CID and HCD but still typically/preferably 
carried out within a slightly modified ion trap or HCD cell [330, 331]. Further, the ions generated differ 
from those of CID/HCD, the fragmentation is not limited by precursor size and is also well adapted for 
PTM characterisation. Hence, ETD is introduced more as a complementing method to CID/HCD, 
particularly useful in top-down experiments [330]. In the Orbitrap Fusion Tribrid MS (previously 
described) ETD fragmentation is possible to perform in the ion trap while simultaneously running the 
orbitrap in parallel.   
3.6.4. Modes of operation 
Depending on the versatility of the instrument available and the conditions of the experiment, the mode 
of operation can be adjusted to optimise the analysis. A vast array of properties and settings are possible 
to affect in LC-MS/MS analysis (although many more are outside our ability to influence) and the 
amount and quality of the data generated is highly dependent on getting them “right” for the particular 
trial at hand.  
When attempting to discover as broad a spectrum of peptides as possible the quality of the data must 
suffice to allow for successful identification but since quality and time go hand in hand, going beyond 
the requirements in quality may result in other peptides not getting enough time. At the other end of the 
operation-mode-span is targeted analysis, where the list of studied analytes (targets) is set from the start 
and intentionally kept short to allow for recording of as much data as possible on the few – also resulting 
in enormous losses of potential information, albeit intended.  
Below are described the principle modes of operation employed in this thesis, by coincidence they 
represent the three most common approaches used in proteomics today; discovery, relative quantitation 
and targeted analysis (i.e., absolute quantitation).    
3.6.4.1. Data-dependent acquisition 
Data-dependent acquisition (DDA) is primarily employed for discovery (shotgun) proteomics and 
means that the MS is given a list of priorities determining what precursors will continue on to 
fragmentation and is in essence aimed at improving data yield [175, 332]. The effect of a number of 
factors on DDA analysis have been evaluated and are re-evaluated now and again as new software 
solutions and instruments appear [333]. The main contributors have focused on the adjustable settings 
with the largest impact on subsequent peptide identification. Reports on the evaluation of resolving 
power, signal threshold for ms/ms precursor, consecutive ms/ms scans, automatic gain control (AGC) 
target for both MS and ms/ms (i.e., the estimated amount of ions available), maximum injection time 
(closely associated with AGC), dynamic exclusion (meant to avoid re-analysing the same precursor over 
and over) as well as collision energy for fragmentation give a good idea of what to focus on during 
optimisation [334-337]. However, it is important to note that sample complexity, pre-treatment, the 
concentration and physiochemical properties of the analytes, chromatographic separation and ultimately 
variations in each unique instrument (reported for in the case of HCD collision energy) requires a degree 
of in house adjustments too.          
If the aim is to achieve a high identification number it is essential that as few peptides as possible go by 
“unnoticed”, but also that recording time is not wasted on “lost causes”. This means that the MS should 
perform full scans frequently to pick up new high-quality candidate precursors for ms/ms, which takes 
time. It is also imperative that each peptide species sent to ms/ms is present in sufficiently high number 
to be properly detected – meaning the instrument must allow for a certain amount of fill time to collect 
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the ions, which obviously takes time. Further, each ms/ms-scan takes time, and high resolution takes 
time; on the other hand, having to re-do the whole experiment because of acquiring low-quality data 
takes more time than anything. 
In conclusion DDA, once optimised for one’s particular pleasure, allows for a good deal of instrument 
automation which is necessary – or essential – for the purpose of successfully performing something so 
inherently intricate as discovery proteomics.  
3.6.4.2. Targeted proteomics 
A mass spectrometer is not inherently able to reliably quantify analytes unaided [26, 209]. This 
shortcoming stems from the need to ionise analytes prior to detection, a quintessential step to the 
technology [348]. A large number of factors affect how large of a portion of a particular analyte is 
ionised from a sample. Most important is the physiochemical nature of the analyte itself, but also 
external factors such as temperature and pressure of the ion source as well as the presence of a large 
number of different analyte species entering the ion source simultaneously [26, 348]. Hence, the relative 
intensity/abundance signal says little about the actual concentration of the analyte within a sample, 
neither does directly comparing intensities of the same peptide between two samples since the sample-
to-sample acquisition variation is generally large [178, 338, 339]. The concept of “label-free 
quantification” should be noted as an important exception since the methods collected under this 
umbrella term claims to be able to allow for unaided quantification based solely on LC and ms/ms-data 
[340]. Label-free quantification does however come with its own unique set of issues which requires 
specialised instrument setups and software to address and several of the approaches are considered 
controversial, such as the concept of spectral counting [178]. 
For the reasons mentioned above and despite the noted exceptions, with current technology, attempting 
concentration determination of individual peptides by means of regular shotgun proteomics can be 
considered quite difficult [183, 341]. However, the ability to produce synthetic (stable) isotope-labelled 
(SIL) analogues of peptides has partly addressed this issue by providing absolute quantification through 
means of comparison to an internal standard. The backside is that the need for a standard makes the 
approach inapplicable for quantification of large sets of peptides, let alone whole peptidomes [178, 342]. 
The synthetic peptides will, barring some potential structural issues, have the same physiochemical 
properties as their native counterparts. Hence, by adding the SIL-peptide to the sample prior to sample 
pre-treatment, both analytes will co-elute from the LC-separation column, enter the ion source 
simultaneously and ionise to the same degree [207, 348]. By incorporating one or several amino acids 
with heavy isotopes of constituent atoms, mainly 13C, 15N and/or 18O, a slight mass-shift between 
synthetic and native peptide is introduced. By performing targeted analysis (i.e., continuously recording 
MS and ms/ms data from said analytes over whole or parts of their elution period) on both peptides it is 
possible to subsequently calculate the concentration of the native peptide by comparison to the SIL 
peptide [353].  
Targeted analysis can be performed in a several ways but here we will mention three common 
approaches; single reaction monitoring (SRM), multiple reaction monitoring (MRM) and parallel 
reaction monitoring (PRM). In practice the difference lies in the number of product ions, or transitions, 
that are monitored, i.e., having their m/z recorded [191, 193, 343]. SRM/MRM analysis is performed in 
a triple quadrupole, employing the Q3 to filter either a single transition continuously (SRM) or for several 
transitions sequentially and repeatedly (MRM) [190, 303] (see figure 9). In PRM analysis the Q3 is 
“replaced” by an Orbitrap mass analyser, allowing for monitoring of all product ions continuously [193].  
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Figure 9: Visualisation of the basic methodology for reaction monitoring employed by triple quadrupole or quadrupole 
Orbitrap. Reprinted with permission from Creative Proteomics, copyright 2018. 
In essence, the difference between the methods lies in speed contra specificity making them suitable for 
different sample materials. In general terms; SRM focus on speed and transition quality, i.e., generating 
many data points of a single transition, but is potentially vulnerable to interference (i.e., is not necessarily 
so specific), PRM on the other hand generates fewer data points because of longer acquisition time, but 
the monitoring of many transitions with high mass accuracy means PRM is highly specific and has a 
low risk of interference, lastly MRM is a compromise between the two [190, 193, 303].  
Analysis and interpretation of transition data is generally aided by specialised software to generate 
comparable spectral information through total peak area calculation; that is, the software determines 
peptide “abundance” by integrating transition intensity over time [189, 344, 345]. By comparing total 
peak areas of native peptide and SIL standard an abundance-ratio is determined which can subsequently 
be used to calculate the concentration of the native peptide from the (known) concentration of the 
standard.    
In this thesis I developed a nano-flow RP-HPLC quadrupole-orbitrap (PRM) method for targeted 
analysis of two endogenous tau peptides, tau 175-190 and its phosphorylated counterpart P-tau 175-190, 
and their heavy SIL analogues. Data analysis of the acquired transitions was performed using open 
source software Skyline (v3.7, MacCoss Lab)[189], which was employed to generate native/standard-
ratio data from the single most intense transition and using the remaining transitions to verify correct 
acquisition. Subsequent concentration determination was performed manually in excel (mainly because 
of a lack of understanding of how to do the same thing directly using Skyline software). The method 
was employed successfully to generate quantitative data in two clinical cohorts, showing an interesting 
application for two peptides in AD diagnosis.        
3.6.4.3. Relative quantitation 
In discovery proteomics it is possible to identify tens of thousands of peptides from a single analysis run 
and targeted proteomics allows for absolute quantification of a subpopulation of the discovered peptides. 
There is however a problem in bridging the gap between the two; how to determine which of the 
discovered peptides should be quantified, which are of potential interest? Finding candidate biomarkers 
by directly comparing analysis data from discovery-sets between AD and HC will require enormous 
populations to have even a remote chance of identifying significant alterations (e.g., peptides only 
present in AD or controls). It is also practically impossible to perform absolute quantification of tens of 
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thousands of peptides (“exploratory quantification”), and hence one either has to choose targets based 
on protein association, i.e., “This endogenous peptide is derived from tau. Must be interesting!” or pick 
them at random or find some other way. 
To address the issue of finding quantitative differences between two (or more) states (or individuals) 
was quite recently introduced a number of peptide labelling techniques that, if employed on the right 
calibre of MS (high resolving and with high mass accuracy), would allow for relative quantitation of 
several multiplexed proteomes/peptidomes at a time [346]. The basic MS-analysis method itself is 
similar to that used for standard shotgun proteomics, so similar in fact that it is shotgun proteomics, but 
with a sufficiently large twist to merit a separate section. The main difference instead lies in sample pre-
treatment and data analysis, with only minor alterations of the DDA-based MS-analysis method [347]. 
The labelling technique employed during the work in this thesis is known as “tandem mass tag” (TMT) 
and was first described by Andrew Thompson et al. in 2003 [348]. There are other similar labelling 
reagents available for MS/MS quantitation, such as “isobaric tags for absolute and relative quantitation” 
(iTRAQ) [349] and the N,N-Dimethyl leucine reagent system (DiLeu) [350]. There are variations in the 
protocols for the different reagents but the general approach is to separately add the isobaric labelling 
reagent to up to ten individual samples, covalently attaching the reagent to specific sites on the peptides, 
quenching the reaction and finally combining the samples (see figure 10).  
 
Figure 10: Schematic protocol and workflow employed for relative quantification by means of 10-plexed tandem mass tag 
(TMT10) isobaric labelling of peptides from complex biological sample matrices. Reprinted with permission from Thermo 
Scientific, copyright 2018.  
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In the case of TMT, the reagent consists of three distinct modules; 1) the amine-reactive group that binds 
to the peptide N-terminal as well as to free ε-amine groups (i.e., on lysine side chain), 2) an isotopic 
balancing group or mass normaliser and, 3) a reporter group [347, 348]. This elegant solution is based 
on shifting the load of 13C and 15N heavy isotopes from the balancing group to the reporter group, thereby 
allowing for ten different isobaric molecules, which will produce reporter ions of escalating mass. The 
result of individual labelling and subsequent mixing of samples is a single composite peak resulting 
from the precursor ion, but as the precursor is fragmented in the HCD cell the distinct masses of each 
reporter ion will result in a ten-step “mass ladder” in the ms/ms spectra with peak intensities 
corresponding to the relative concentration of the precursor in each original sample. Various alterations 
to the MS method need to be employed as well as substantial data analysis and interpretation by 
specialised software is required following LC-MS/MS analysis, but in general terms the price-tag is 
more complex than the actual application. 
The importance of this concept cannot be exaggerated, even though there are of course associated 
problems – possibly most importantly that one relies too heavily on the generated data [24, 346, 351]. 
However, the ability to multiplex samples in this manner both improves throughput substantially and 
may even aid in the detection and identification of low-abundant peptide species [352]. Further and most 
importantly, the technique has greatly reduced the problems involved in discovery of novel biomarker 
candidates by providing the means for relatively reliable relative quantification of peptides between 
individual samples.  
3.6.5. Hybrid mass spectrometers 
There is a multitude of MS instruments/technologies suitable or specialised for different applications, 
such as the triple quadrupole MS for rapid, sensitive and robust targeted analysis, the Fourier transform 
ion cyclotron resonance (FT-ICR) MS for higher resolving and accurate mass-analysis or the previously 
described Orbitrap which is both fast and high resolving [181, 305, 353, 354]. Because of their distinct 
capabilities, several mass analysers are often combined in a so-called hybrid mass spectrometer, that 
combines the particular strengths of the individual analysers and enables specific modes of operation. 
The vast majority of MSs employ hybrid combinations of mass analysers one of the most common is 
the Q-‘mass analyser’; that is, a single quadrupole followed by an ion trap and/or mass analyser. The 
triple quadrupole (QQQ) is one of the earliest examples of this setup, where the last Q work as a second 
mass analyser (and the middle Q is a trap/collision cell), but other, distinct analysers were soon 
introduced as well, for instance a time-of-flight (TOF) and subsequently the Orbitrap.  
Without getting into too much detail, the quadrupole introduces features such as precursor selectivity 
and the TOF provides a higher resolution and mass accuracy compared to the “QQQ + detector” setup. 
This particular setup turned out to be very useful in proteomics since it allowed for continuous high 
resolving analysis of a complex stream of even more complex ionised analytes, i.e., peptides [22, 355]. 
Later was introduced the Orbitrap mass analyser which was another “game-changer” since it allows for 
even higher resolution and mass accuracy [315, 317, 356].    
Below follows a brief description of the two instruments employed for all MS analyses performed in the 
works of this thesis; the Q Exactive MS and the Orbitrap Fusion Tribrid MS, both combining the 
Orbitrap mass analyser with either a single quadrupole or a complete LTQ. By running mass analysers 
in tandem, it is possible to combine the features of the two at the expense of instrument size. In both 
instruments described below the speed and mass filtering capabilities of a quadrupole have been added 
to the mass accuracy of the Orbitrap. The result are instruments, which may be employed for both 
exploratory work as well as selective monitoring of specific analytes from complex samples.   
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3.6.5.1. Q Exactive 
The Q Exactive was introduced to be a compact and robust workhorse in proteomic analysis. The Q 
Exactive is an update or alternative from a previous system, the linear ion trap (LTQ) Orbitrap, which 
replaces the LTQ with just a Q, a single quadrupole mass filter, and incorporates an HCD cell 
downstream of the C-trap instead of the CID cell of the LTQ (see figure 11). The setup allows for both 
high-resolution acquisition with high mass accuracy as well as two modes of targeted analysis, PRM 
and multiplexed selected ion monitoring (SIM) [357]. Further, the introduction of a separate and 
dedicated collision cell comes with a few advantages, such as improved fragmentation, ability to monitor 
low-mass ions and thereby the possibility to perform relative quantification using isobaric labelling. 
  
Figure 11: Schematic of the Q Exactive hybrid Orbitrap mass spectrometer. Reprinted with permission from Thermo 
Scientific, copyright 2018. 
Although speed and resolution correlate negatively and a large number of factors impact the actual data 
quality, the Q Exactive is capable of high frequency MS acquisition (~8 Hz) at resolutions around 70 000 
FWMH (top resolution ~140 000 at 1.5 Hz).  The mass accuracy is high also at lower resolution; thus, 
the resolution in ms/ms mode is chosen depending on the application 
Here the Q Exactive was used for high resolution discovery peptidomics of samples prepared by TFC 
(paper II) as well as for relative quantitative analysis of an isobaric labelled clinical cohort (paper III).  
3.6.5.2. Orbitrap Fusion Tribrid 
Compared to the Q Exactive, the Orbitrap fusion tribrid (OFT) is substantially larger and comes with an 
even higher resolving power (maximum 450 000 FWMH), is equipped with a complete LTQ, including 
a quadrupole mass filter as well as a detector, enabling parallel operation with the Orbitrap mass analyser 
(see figure 12). Further, the system enables several modes of fragmentation with CID, HCD and 
ETD/EThcD (electron-transfer dissociation) thus allowing for an even greater amount of information to 
be acquired from the analytes, if required. In addition, it took 2 to 3 months “vacation” each summer.    
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Figure 12: Schematic of the Orbitrap Fusion Tribrid mass spectrometer. Reprinted with permission from Thermo Scientific, 
copyright 2018. 
The OFT was the main analytical tool for most of the work in this thesis and was employed both for 
discovery and quantitative analysis. In paper I the instrument recorded high quality data in discovery 
mode, resulting in the identification of more than 18 000 endogenous peptides. In paper III the Fusion 
was employed both for relative quantitation of an isobaric labelled clinical cohort in data-dependent 
acquisition mode as well as in targeted top-down analysis; and finally, in paper IV it was used for 
absolute quantitation by means of a PRM method. 
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 Results and discussion 
The overall goal of this thesis has been to develop novel biomarkers of NDs, primarily AD. The search 
for clues to understanding the machinations involved in neurodegeneration has been going on for a long 
time [358, 359]. Similarly, the sample material chosen was traditional for its purpose, CSF, is for many 
reasons (see above) considered well suitable for the study of the CNS by proxy. However, the analytes 
did differ from the mainstream to some extent. Compared to most of the studies carried out for the 
purpose of investigating the CNS the work performed in the papers described here focused on the 
endogenous peptide content of CSF.  
Of the four papers included in this thesis, the first two primarily involve development of methods for 
the purpose of acquiring, detecting and identifying endogenous peptides in general. In slight contrast, 
the last two papers also included targeted analysis of three of the peptides identified as a result of the 
previous work. In paper I, extensive sample preparation, implementation of state-of-the-art LC-MS/MS 
equipment and a novel peptide identification strategy was employed to aid in the identification of 
endogenous peptides in general, and low-abundant ditto in particular. Paper II involved the study and 
optimisation of a chromatographic technique which would allow for rapid sample preparation intended 
to be applicable in future targeted analysis of endogenous peptides, for instance in MS-based biomarker 
assays. The third paper explored a novel approach to endogenous peptide quantitation in discovery 
proteomics; employing TMT isobaric labelling and spectral analysis based on clustering of the ms/ms 
data. Paper III also included targeted analysis, first to identify one particularly interesting peptide and 
subsequently to validate its potential as a biomarker in a clinical cohort. Finally, in paper IV was targeted 
analysis of two peptides from protein tau, identified in paper I and subsequently in paper II, as the first 
ever reported endogenous tau peptides performed. The tau peptides were evaluated in two clinical 
cohorts for their potential use as diagnostic markers for AD as well as for differential diagnosis of AD 
compared to PD and PSP. 
4.1. Paper I: Expanding the CSF peptidome 
It was hypothesised that previous studies of the CSF endopeptidome had only scratched the surface and 
that further discoveries could be made, especially if peptides in the lower concentration ranges could 
somehow be accessible for detection. As previously noted, one of the major issues in MS-based studies 
of biological materials is the sheer number of analytes present, and in particular the fact that a few 
analytes are excessively highly represented [9, 93, 118, 235, 360]. To attempt to overcome this hurdle, 
extensive sample preparation protocols for pre-treatment, cleaning/de-salting and deconvolution of 
endogenous CSF peptides for analysis by LC-MS/MS, as well as software-based peptide identification 
strategies of the resulting data were developed. 
A protocol previously developed in house by Mikko Hölttä et al. (2012) [228] for selective purification 
of endogenous peptides from CSF, based on MWCO-filtration, was further developed and optimised. 
Primarily the step for chemical pre-treatment of the sample was modified and off-line RP-HPLC pre-
fractionation, based on the work of Tanveer Batth and colleagues (2014) [262], was introduced 
following peptide purification (MWCO-filtration). On-line RP-HPLC was carried out over a 180 min 
gradient on an Ultimate 3000 RSLC nano-flow system, allowing for a high degree of peptide separation 
prior to ms/ms-analysis performed on an Orbitrap Fusion Tribrid mass spectrometer (both from Thermo 
Scientific). Finally, ms/ms-data was analysed employing a combination of three different peptide 
identification algorithms. A schematic representation of the workflow has been included in figure 13. 
40 
 
 
Figure 13: The workflow developed in paper I for attempting identification of as large a section as possible of the CSF 
endopeptidome. Brief step-by-step explanation; 1) sample extraction by means of lumbar puncture followed by removal of 
insoluble CSF components by means of sedimentation through centrifugation, 2) chemical sample pre-treatment meant to 
denature higher protein structures, optional addition of standards or isobaric labelling, 3) removal of proteins through 
ultrafiltration (MWCO), 4) removal of soluble CSF components and excess reagents as well as small hydrophobic CSF 
components such as lipids, 5)off-line peptide pre fractionation and concatenation over an alkaline mobile phase gradient, 6) 
on-line LC-MS/MS analysis of each concatenated fraction, 7) peptide identification through processing of raw ms/ms-data by 
three peptide identification algorithms, comparison of IDs and evaluation of results. 
Since the amount of sample material which can be analysed at-a-time by nano-HPLC MS/MS is limited 
(this being one of the defining caps for detection of low-abundant peptide species rather than the 
sensitivity of the instrument) splitting the total peptide content into sub-fractions allowed for an increase 
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in the total amount of initial sample material used in the protocol [257, 353]. Thus, employing pre-
fractionation causes that the relative concentration of each individual peptide species was increased, 
aiding in the detection of low-abundant peptides [257, 258, 262, 361]. Another effect of fractionating 
the sample prior to analysis is that the complexity (in practice defined as the number of individual 
peptide species eluting from the HPLC-column at any given gradient time-point) is reduced, giving the 
MS a better opportunity to detect each analyte [251, 256, 257].  
The last alteration made to the original protocol involved identification of peptides from ms/ms-data. 
Compared to peptides generated from proteins by means of proteolytic degradation in vitro (proteomics), 
endogenous peptides tend to receive a low identity score when employing proteomic software for 
ms/ms- data analysis [173, 206, 285, 352]. This issue was partially addressed by engaging a machine 
learning feature, Percolator™, available in ion-fingerprinting-based software (Mascot, SequestHT), and 
partially by analysing the data with a tertiary software based on de-novo sequencing (PEAKS). 
Percolator adapts the scoring algorithm iteratively based on respective common features of the subsets 
of most and least confident (highest/lowest scoring) peptide sequence match (PSMs) [362, 363]. Since 
the employed proteomics softwares were originally developed for identifying peptides, generated 
through proteolytic activity in vitro, they may be ill-adapted for endogenous peptides, particularly if said 
peptides contain PTMs [24]. The percolator feature seemed to alleviate the inherent 
problems/incompatibilities to some degree when performing peptidomics with tools developed for 
proteomics (see figure 14). 
 
Figure 14: Comparison of number of identified endogenous (A, C) and tryptic (B, D) peptides with Mascot (A, B) and 
SequestHT (C, D). PSM were scored using the default scoring algorithm of the respective software (blue) as well as the machine 
learning-based algorithm, Percolator (yellow). 
A third algorithm, employed by de novo-sequencing software PEAKS, was also engaged to compare the 
functionality of this strategy to identify endogenous peptides. Very briefly; de novo-sequencing 
algorithms goes through individual ms/ms-spectra and, by measuring distance (in m/z) between detected 
peaks of fragment ions, sequentially “builds” the sequence one (or a few) amino acids at a time, adding 
a so called “sequence tag” to each spectra including a confidence value for the particular peptide 
sequence [364]. Following the initial sequencing the peptides can be compared to a database. However, 
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the basic concept of de novo-sequencing allows for unbiased identification of peptide sequences5 and is 
especially useful for identifying peptides containing PTMs and to pinpoint their most likely position 
[365, 366].  
By further developing the protocol for peptide purification and acquisition and employing pre-
fractionation of the sample resulted in a near 10-fold increase in acquired ms/ms spectra during analysis 
compared to the previous protocol. The 10-fold ms/ms spectra increase, depending on which individual 
proteomics software was employed (see figure 15), translated to a similar increase in PSMs and a 5- to 
8-fold increase in actual peptide identification. Importantly, we were also able to show that it was 
possible to combine the identification results of the employed softwares without running into multiple 
testing issues (or we could show that the extent of the multiple testing issues was smaller than the set 
level of FDR of 1%).  
Due to the small total identification overlap, or consensus, between search algorithms of less than 15% 
we concluded that not combining the resulting peptide identification would result in substantial 
information loss. Hence, we found it reasonable to consider the identification results complementary 
rather than comparative and combined all unique peptide IDs into a single library of endogenous CSF 
peptides containing 18.031 entries resulting from three separate analyses of pooled CSF from two 
different sources (all data available via ProteomeXchange under identifier PXD004863). The approach 
has been suggested previously by, among others, Shteynberg et al. (2013) as an option to optimise data-
utilisation in shotgun proteomics [367]. However, we were first in showing the substantial benefit when 
studying endogenous peptides.   
 
Figure 15:Comparison of proteomics software for identification of endogenous CSF peptides. 
Over 1900 proteins were represented by endogenous peptides in the sample set of two CSF pools. 
Among these were microtubule-associated protein tau (6 peptides), amyloid precursor protein (213 
peptides, 58 of which spanning the amyloid beta sequence), NfL and NfH (1 unique peptide each) and 
                                                     
5 Ion-fingerprinting algorithms predicate peptide identification on comparison to in silico-generated fragment ion 
libraries which requires pre-existing information on the studied proteome. 
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a further 60 proteins with known or suspected involvement in neurodegeneration were represented by 
nearly 3000 peptides [9, 221, 368, 369]. 
We concluded that the protocol employed here was successful for the purpose of identifying previously 
undetected sections of the human CSF peptidome. The workflow is labour intensive and substantial 
sample handling results in increased risks of introducing contaminants. However, this and subsequent 
studies employing the workflow (see paper III) indicate that investing time and resources in a large scale 
initial trial may result in a long list of potential candidate markers for further studies. Finally, with the 
work presented in this paper we were able to show the scale of the human CSF endopeptidome – simply 
containing such a large amount of information would warrant further study in the opinion of this 
researcher. 
4.2. Paper II: Turbulent Flow Chromatography 
In paper II was the potential usefulness of TFC for rapid sample preparation of CSF for subsequent LC- 
MS/MS analysis of the endogenous peptide content investigated. 
As a result of the identification of a large number of endogenous CSF peptides in the previous study 
(see paper I) it was hypothesised that the CSF peptidome could be a source of future biomarkers for 
CNS disorders. Biomarker assays based on MS analysis are slowly being considered for introduction 
into clinical routine, primarily as a compliment to traditional assays based on immunoprecipitation (IP) 
[13]. There are various reasons for the slow development, but among the major issues is the overall 
lower throughput of MS-based assays, primarily caused by the extensive sample preparation required 
[351, 370, 371]. The method investigated in paper II has the potential to address parts of the throughput 
problem as well as offer a highly automated, specific and sensitive biomarker assays-protocol for future 
clinical routine analysis based on MS [275, 372, 373]. 
In paper II we evaluated various factors previously reported to impact peptide acquisition when 
employing TFC for separation of peptides from proteins and compared the results to the protocol 
currently in use (i.e., peptide acquisition by means of MWCO-filtration). 500 µL sample aliquots, 
corresponding to 250 µL CSF pre-treated to degrade protein/peptide aggregates, were separated over a 
Cyclone™, 0.5 x 50 mm, “TurboFlow HTLC”-column (Thermo Scientific) operated offline (i.e., not 
connected to any analysis instrument) on an Ultimate 3000 normal flow rapid separation liquid 
chromatography (RSLC) system (Dionex). Following preparation, the resulting endogenous peptides 
were analysed by nano LC-MS/MS on a Q Exactive (Thermo) system.  
Primary factors for testing involved mobile phase pH (3 or 9) and loading flow (0.25, 0.5, 1.0 and 2.0 
mL/min) and evaluation of TFC-effect was primarily based on number of peptide IDs resulting from 
each treatment, as well as ID overlap and variation in a subsequent LC-MS/MS analysis of the sample 
(see table 1). Further evaluation employed SDS-PAGE gel separation of the protein content of the waste 
and eluting fractions to visualise the ability to remove the protein content of the CSF at the mentioned 
flow-rates (see figure 16). 
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Table 1: Compilation of analysis result from samples prepared by TFC at three different loading flows: 0.5, 1.0 and 2.0 mL/min, 
and over two mobile phase pH: 3 and 9, and compared to the current standard protocol for separation and acquisition of 
endogenous peptides; MWCO ultracentrifugation 
 pH 
Flow-rate 
[mL/min] 
Average 
peptide IDs 
CV [%] 
Total # 
Peptide IDs 
ID overlap 
TFC separation 
3 
0.5 936.3 5.4 1526 508 (33.28%) 
1.0 587.0 21.2 968 321 (33.16%) 
2.0 333.0 11.0 462 226 (48.91%) 
9 
0.5 1136.0 7.1 1949 555 (28.47%) 
1.0 710.0 10.9 1156 377 (32.61%) 
2.0 465.0 2.8 627 303 (48.32%) 
MWCO 
ultracentrifugation 
3 n/a 1354.7 10.1 2260 679 (30.04%) 
Initial trials concluded that a flow of 0.25 mL/min resulted in a column backpressure reaching the limits 
of the LC, causing the LC to shut down or, in several cases, capillaries and fittings to burst. From the 
PAGE gel it is possible to see that the amount of protein in the fraction passing over the column during 
loading and elution are roughly similar at 0.25 mL/min. At a flow-rate of 0.5 mL/min, the pressure 
increase during loading was significantly lower, actually lower than at both 1.0 and 2.0 mL/min as well 
as 0.25 (data not shown), and no column blocking was noted. This indicates that, for this particular 
column, the sought-after turbulence of the liquid bulk occurred at some point between 0.25 and 0.5 
mL/min, and further confirm that turbulent flow has a dramatic impact on protein—column interaction 
which has been previously reported [374-376]. From the PAGE gel, it is also possible to see that the 
protein amount in the wash fraction increases and, reversely, decreases in the eluting fraction with higher 
flow-rates. These observations support previous findings by Herman and Edge (2012) and others who 
suggested that TFC can be employed as an adjustable MWCO filter for protein exclusion by altering the 
flow-rate [377-379].  
 
Figure 16: SDS-PAGE gel separation of protein content from fractions collected during TFC sample loading phase (i.e., 
“Wash” or elution phase, “Elute”, as well as the content of the collection tube following MWCO-filtration); y-axis is presented 
as an molecular weight “ladder” and the unit is in kDa. 
Results further indicate that, once turbulence has been achieved, increasing flow-rate correlates 
reversely with the number of endogenous peptides identified during subsequent analysis, i.e., the higher 
the flow-rate the smaller the number of peptide IDs.  
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Finally, the effect of mobile phase pH is small, but a higher pH seems to correlate with a slightly higher 
number of identified peptides. However, from figure 17 it is clear that the identification overlap is small 
and that two different subsets of the CSF peptidome are obtained when applying different mobile phase 
pHs for TFC separation. The cause is likely a question of peptide properties; that is, some peptides are 
retained better or worse as a consequence of mobile phase pH [380, 381]. Herman et al. (2012) noted 
that the size exclusion properties of the TFC column at different flow-rates were affected by the pH 
employed, said results regarded proteins but they may still indicate a potential effect also on peptides 
[378]. The results indicate that a future assay will have to adapt and optimise the pH of the mobile phase 
to suit the targeted peptides.   
 
Figure 17: Evaluation of pH-dependence in peptide identification. Venn diagrams showing number of peptide IDs from 3 
repeats each from HPLC-MS/MS analyses of samples prepared with a TFC mobile phase gradient at pH 3 or 9 and at flow-
rates a) 0.5 mL/min, b) 1.0 mL/min and c) 2.0 mL/min. d) histogram comparing molecular weight distribution of identified 
peptides from samples prepared by TFC at a flow-rate of 0.5 mL/min at either pH 3 or 9. 
The initial results indicate that TFC is applicable for the purpose of selective separation of peptides from 
the protein content of CSF, comparable to the currently employed method. As previously described, if 
endogenous peptides can be employed as biomarkers they would be a functional alternative to IP-based 
assays. As with an IP, an assay based on endogenous peptides does not need to perform a lengthy protein 
degradation, but measures what is already present in the sample. The current protocol for acquisition of 
endogenous peptides, based on MWCO-filtration, requires comparatively little time (compared to a 
standard proteomics protocol) to ready a sample for analysis. Our study shows that a protocol for the 
same purpose but employing TFC for peptide acquisition would reduce time/sample-requirement 
further. An LC-setup including a primary TFC step could allow for an (almost) online patient-to-mass 
spectrometer setup, improving throughput and reducing sample handling [271, 273, 376, 378]. If this 
increased throughput and automation could be realised the unchallenged specificity of mass 
spectrometry could properly compete with any IP-based biomarker assay.  
4.3. Paper III: Spectral clustering and pleiotrophin 
The main goal of the study performed in paper III was, to identify novel endogenous biomarkers for 
NDs, primarily AD. To this end, the tandem mass tag (TMT) isobaric labelling technique to perform 
multiplexed (10-plexed) LC-MS/MS analysis of samples of endogenous CSF peptides from two clinical 
cohorts was implemented. The first, or “discovery”, cohort consisted of a total of 120 individuals 
clinically diagnosed with AD (n=40) and MCI (n=40) as well as non-demented controls (n=40). The 
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group MCI was split after a follow-up clinical diagnosis into three sub categories: stable-MCI, MCI-S 
(n=23), MCI progressed into AD, MCI-AD (n=14) and “other ND” (n=3) – subsequently excluded from 
the study. The second, “validation”, cohort consisted of a total of 60 individuals clinically diagnosed 
with AD (n=15), PD (n=15) and PSP (n=15) as well as healthy controls (n=15). Samples were prepared 
according to the protocol based on MWCO filtration for selective acquisition of endogenous peptides 
However, the successful quantitation and discovery of new biomarkers was achieved through the 
application of a novel proteomic/peptidomics data analysis strategy, meant to address and overcome a 
severe issue inherent in current identification-driven analysis workflows.  
An example of an encounter with this issue can be found in Paper I where we performed a small study 
on peptide identification success rate. When evaluating ms/ms data in a set of endogenous peptides we 
found that out of 269 945 ms/ms spectra only 3 094 PSMs were obtained, , corresponding to an 
identification success rate of 1.1%. A similar evaluation of a sample of tryptic peptides gave a success 
rate of 8.6% (36 886 PSMs from 427 613 ms/ms spectra), which is better, yet the overall conclusion is 
that a large amount of data does not result in any peptide information.  
The problem partly stem from the proteomics algorithms employing protein sequence databases for 
generating peptide IDs at a given FDR [173]. Peptide IDs are acquired from raw data by comparing 
acquired MS/MS spectra to in silico generated m/z libraries – an approach known as fragment ion 
fingerprinting [382]. The method is fast but is also necessarily restrictive; peptides from sequences not 
already present in the database cannot be identified and the number of possible PTMs is strictly limited 
[383]. Further, peptides not having the correct characteristics, such as a particular amino acid at the 
correct termini or presenting unsuitable fragmentation spectra, are likewise discarded. The logic is 
sound: do not waste time and effort on performing quantitation on data that will anyway turn out 
uninterpretable. However, the quantitative and spectral information can still be employed, but may need 
further analysis [384].  
To overcome this problem, we developed a protocol based on quantitation of clustered ms/ms-spectra 
prior to actual peptide identification (see figure 18) [384]. The idea being to quantify first, rank the 
clustered spectra according to how well they separated diagnostic groups and to lastly, attempt to use 
the ms/ms spectra within the most high-ranking clusters to identify the peptide [384, 385]. Groups of 
spectra are clustered together based on precursor m/z, charge state and fragment ion patterns [386]. TMT 
reporter ions from each cluster allows for relative quantitation between individuals in the study groups. 
This, in turn, permits each individual cluster to be ranked according to ability to separate groups of 
diagnoses prior to acquiring a peptide ID.   
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Figure 18: Comparison of the quantitation- and identification-driven workflows. The quantitation-driven workflow (a) initially 
clusters ms/ms spectra from all TMT sets (and all replicates) based on similarities in precursor m/z, charge state and fragment 
ion patterns through employment of an algorithm. The TMT reporter ions of individual clusters allow for determination of the 
relative individual peptide abundance within the cluster and, subsequent ranking of each cluster based on the ability to separate 
diagnostic groups. Finally, the highest-ranking clusters are identified, either by ion fingerprinting/de novo-sequencing (if 
possible) or through separate targeted analysis. In the identification-driven workflow (b) ms/ms spectra are initially converted 
to PSMs and matched by peptide sequence. TMT reporter ions are then used to quantify individual peptide abundances, 
peptides are ranked according to their ability to separate study groups and finally biomarker candidates are selected. 
The result is one or several clusters which separate diagnostic groups sufficiently to merit further study. 
At this point the ms/ms-data of the fragment ions in the cluster of interest is employed to generate a 
peptide ID, if possible, which is subsequently used in when attempting targeted analysis for confirmation 
of the peptide as a potential biomarker. In table 2 is presented the top 20 highest ranking clusters 
resulting from processing of more than 1.2 million ms/ms spectra from LC-ms/ms analysis (including a 
total of four replicates) of the discovery cohort. Cluster ranking was based on increasing AUC value (in 
%) from a receiver operating characteristic (ROC) curve analysis of the ability to discriminate AD from 
non-demented controls. 
  
48 
 
 
Table 2: List of the top 20 clusters in the discovery set, ranked according the calculated AUC of their ability to separate AD 
and non-demented controls. Column descriptions from left to right: Cluster # (identifier); detected m/z value; detected charge-
state; average p-value of cluster similarity to the spectra that are part of a cluster; the number of study subjects in which the 
cluster was quantified; the relative median difference in abundance between AD and non-demented controls; calculated AUC 
(from ROC analysis) for discriminating between AD and non-demented controls; successful identification of peptide sequence; 
the identified peptides’ protein of origin. 
Cluster 
# 
m/z Charge Avg p of 
cluster 
similarity 
Subjects 
(n) 
Relative 
diff. AD 
vs HC 
AUC - 
HC vs 
AD 
Peptide 
Sequence 
identified 
Protein 
affiliation 
25327 684.044 3 0.003 60 9%** 0.98* -   
7367 794.115 5 0.073 119 222%** 0.97* -  
11904 816.467 4 0.001 61 18%* 0.95* -   
82223 794.885 2 0.000 111 29%** 0.93* √ Clusterin 
61266 1380.71 3 0.000 70 -19%** 0.93* -   
10464 786.901 4 0.002 59 22%** 0.93* -  
69078 664.799 2 0.000 94 18%** 0.92* -   
4243 696.457 5 0.000 59 103%* 0.92* -  
78065 748.382 2 0.001 120 37%** 0.90* √ Osteopontin 
33238 787.612 3 0.001 69 20%** 0.90* -  
9084 836.597 5 0.000 86 47%** 0.90* -   
71623 685.336 2 0.000 61 13%** 0.90* -  
34935 810.044 3 0.001 58 16%** 0.90* -   
1889 427.579 3 0.014 120 15%** 0.90* -  
36033 823.45 3 0.006 120 18%** 0.90* √ ApoE 
87816 848.511 2 0.002 69 18%** 0.89* -  
6405 690.794 4 0.000 60 13%* 0.89* -   
32527 777.426 3 0.001 68 13%** 0.88* -  
13290 840.651 4 0.038 111 18%** 0.88* √ Secretogranin-1 
12243 911.104 5 0.000 70 -28%** 0.88* -  
53204 1088.54 3 0.000 60 4%* 0.88* -   
** Indicates statistical significance (p < .001) 
* Indicates statistical significance (p < .05) 
The 2nd top most cluster, #7367, was quantifiable in 119/120 subjects and presented a ROC-AUC of 
0.97% with a relative median increase in abundance between AD and non-demented controls of 222%. 
Further, plotting individual intensity ratios of the cluster, grouped according to diagnosis showed an 
escalating pattern corresponding to disease severity (see figure 19). This suggested a potentially highly 
useful biomarker candidate for AD. However, initial attempts to identify a peptide sequence failed, as 
did identification of 15 out of the 19 remaining clusters – thoroughly introducing the backside of this 
workflow.  
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Figure 19: Scatterplot of TMT reporter ion intensity ratio in cluster #7367 from the discovery cohort, grouped according to 
diagnosis of; non-demented control (Ctrl.), stable MCI (MCI-S), MCI progressed into AD (MCI-AD) and AD. 
Making a long, intense and tedious process of analytical detective work (well worth reading about in 
[387]) into a single sentence; cluster #7367 was eventually identified as peptide sequence 151-
AESKKKKKEGKKQEKM-166, of protein pleiotrophin (PTN) with a monoisotopic mass of 3966.54 
Da. The PTN protein has been shown to be involved in embryonic and early post-natal neural 
development as well as in angiogenesis and tissue regeneration [388-391]. However, in later life only 
certain types of neuronal cells in the hippocampus and cerebral cortex express the protein [392], putting 
it quite specifically in the middle of the area most prominently affected in AD.     
Validation of the endogenous peptide PTN 151-166 as a potential AD biomarker was performed in a 
secondary CSF material (the validation cohort, N=60), consisting of individuals clinically diagnosed 
with AD, PD, PSP as well as healthy controls (n=15 of each). Furthermore; a majority of the CSF 
samples (those with sufficient volume still remaining) were analysed by enzyme-linked immunosorbent 
assay (ELISA) to determine the concentration (pg/mL) of core AD biomarkers Aβ1-42, T-tau and P-tau. 
The CSF samples were prepared in the same manner as the discovery cohort, employing TMT-10 for 
multiplexed quantitation, but also employing targeted Orbitrap PRM analysis of the +5 charged PTN 
151-166 precursor (m/z: 794.115 Da), recording all resulting fragment ions to ensure high quality 
spectra.  
The approach was successful, and results from the targeted LC-MS/MS analysis of PTN 151-166 in the 
validation cohort are plotted in figure 20. Analysis of the data showed that PTN 151-166 was 
significantly increased in AD compared to control, however not compared to PD or PSP. Similarly, 
ROC curve analysis gave an AUC of 0.80 for specificity of PTN 151-166 when separating AD from 
control, but 0.55 and 0.67 when discriminating between AD/PD or AD/PSP respectively. In comparison 
to the core AD biomarkers PTN 151-166 proved to be less specific for the purpose of separating AD 
from controls. However, it should be noted that the peptide turned out to be a rather tricky analyte and 
further method development could result in improvements of its diagnostic performance. Finally, the 
fact that PTN 151-166 does separate AD from controls with a verified specificity of 80% suggests some 
involvement in the pathological process and may indicate future applicability in the study of the disorder. 
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Figure 20: Scatterplot of the relative abundance endogenous peptide PTN 151-166 from the validation cohort, grouped 
according to diagnosis of; AD, healthy controls, PD and PSP.  
4.4. Paper IV: Tau protein-to-peptide ratio 
In Paper I was identified the first ever reported endogenous peptides from protein tau; furthermore, 
several of the identified peptides spanned the analytically interesting site threonine-181 (Thr-181). The 
CSF concentration of tau (T-tau), measured by ELISA, is a biomarker for general neuronal/axonal 
trauma [35]. T-tau, along with the CSF concentration of tau phosphorylated at Thr-181 (P-tau) are also 
used as biomarkers for AD. The identified tau peptides merited further study in order to evaluate whether 
they could be of further interest as biomarkers for neurodegeneration. To this end a trial with the aim of 
absolute quantitation of one of the peptides, and its phosphorylated counterpart, in clinical cohorts was 
conducted. 
Endogenous peptide acquisition and purification was performed according to the previously described 
protocol (paper I) but excluding the pre-fractionation step prior to HPLC-MS/MS analysis. SIL peptides 
corresponding to their native analogues – the 16 aa long tau 175-190 and its phosphorylated counterpart, 
P-tau 175-190, were added to the CSF sample as an internal standard of known concentration. An LC-
MS/MS-analysis method (PRM) for targeted analysis of the two endogenous tau peptides and their 
isotopically labelled standard counterparts was developed and optimised on an Orbitrap Tribrid Fusion 
MS, employing the powerful combination of a quadrupole mass filter and Orbitrap mass analyser. The 
method was primarily employed for confirming detection and determining concentration of both tau 
175-190 and P-tau 175-190 by addition of their SIL peptide counterparts in pooled CSF (see figure 21). 
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Figure 21: Confirmation of identification and absolute quantitation of tau 175-190 (top row, a & c) and P-tau 175-190 (bottom 
row, b & d). On the left side are fragment ion spectra of tau 175-190 (a) and P-tau 175-190 (b), both presented in red, 
visualising similarity in fragmentation with the corresponding SIL peptides (blue) as well as the expected mass shift resulting 
from the presence of heavy isotopes. On the right are extracted ion chromatograms (XICs) of the precursors of the native (red) 
and SIL (blue) peptides, meant to visualise similarities in chromatographic behaviour and co-elution.  
CSF from a group of healthy control subjects (HC, n=15) as well as individuals diagnosed with AD 
(n=15), PD (n=15) and PSP (n=15) was prepared and analysed. In parallel was CSF T-tau and P-tau 
analysed by ELISA on aliquots of the same material, following the standard protocol employed for 
measuring these core AD biomarkers. Plotting the measured concentrations from the PRM analysis 
showed no correlation between the concentration of either endogenous peptide and diagnosis (see figure 
22 a and b). Further, there was a low or negligible correlation between the measured concentration of 
T-tau and P-tau protein and their corresponding endogenous peptides (see 22 c and d).  
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Figure 22: Correlation between total tau protein/total concentration of phosphorylated tau measured by ELISA and 
corresponding endogenous peptides: tau 175-190 and P-tau 175-190 in fmol/mL 
The near complete lack of correlation between proteins and peptides led us to speculate on what origin 
the endogenous peptides may have. It was possible that tau 175-190 could be the result of normal, non-
pathological, processing of tau protein, and P-tau 175-190 conversely the result of ditto processing of 
phosphorylated tau [115, 122]. If this was the case it might suggest that the endogenous peptides could 
allow for new insights into the protein. Further, the endogenous peptides could potentially be employed 
to normalise for the protein expression and improve diagnostic performance. The model for this 
hypothesis was the reported use of endogenous peptide Aβ1-40 to compensate for and reduce variations 
in Aβ1-42 concentration caused by abnormally high/low expression of APP [103, 104].  
Figure 23 shows the diagnostic group separation of AD to HC, as well as to PD and PSP, when 
employing a) T-tau only or b) T-tau/tau 175-190; in c) and d) are corresponding plots for P-tau and P-
tau/P-tau 175-190. Although the group separation in this particular cohort is initially good, the 
protein/peptide normalisation has a notable effect, visualised by ROC curve analyses included in figures 
23 e) and f). Further, the effect size for the AD/HC group-separation was significantly increased for T-
tau/tau 175-190 (Cohen’s d = 1.98) compared to T-tau alone (d = 1.72); a similar increase in effect size 
was noted for AD/HC when employing P-tau/P-tau 175-190 (d = 1.72) compared to P-tau only (d = 
1.53) (see supplementary table x).  
 
53 
 
 
Figure 23: Scatter plots of group separation and ROC analysis of diagnostic accuracy in the discovery cohort. The ability to 
separate disease groups/healthy controls based on (a) t-tau concentrations. (b) t-tau/tau 175-190 molar ratio. (c) P-tau 
concentrations and (d) P-tau/P-tau 175-190 molar ratio. (e. f) ROC curve analysis showing the effect on diagnostic precision 
when separating AD from healthy controls based on protein concentration alone compared to protein/peptide ratio. 
Further study of the set suggested the main effect of employing the protein-to-peptide ratio was in a 
reduction of group variation, adding to the hypothesis that the endogenous peptides can be employed to 
compensate for normal expression and processing of tau [393]. 
A second cohort consisting of 40 clinically diagnosed individuals of AD (n=16) and HC (n=24) was 
analysed to study the phenomena further. The results are shown in figure 24 and, albeit (or possibly 
because of) the groups are less well separated in this cohort, the effect of protein-to-peptide 
normalisation is clear; group separation is significantly improved.  
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Figure 24: Scatter plots of group separation and ROC analysis of diagnostic accuracy in the validation cohort. The abillity to 
separate AD from healthy controls based on (a) t-tau concentrations. (b) t-tau/tau 175-190 molar ratio. (c) P-tau 
concentrations and (d) P-tau/P-tau 175-190 molar ratio. (e. f) ROC curve analysis showing the effect on diagnostic precision 
when separating AD from healthy controls based on protein concentration alone compared to protein/peptide ratio. 
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 Conclusions  
The major findings presented in this thesis include a substantial expansion of the known CSF 
endopeptidome, discovery of a number of endogenous peptides from proteins of known or suspected 
interest in the diagnosis and study of NDs and, introduction of three potentially useful biomarkers for 
AD. However; most of the present work has been spent developing, adapting and optimising methods 
for the study of endogenous CSF peptides by means of LC-MS/MS analysis, as well as exploring 
alternate approaches to peptide identification. Since there is little practical difference between biological 
sample materials, at least not insurmountable differences, the methods developed for CSF 
endopeptidomics might with small alterations be applicable for any biological substance, including 
tissue lysates. Hence, among the main advances presented may be the methods and protocols for the 
successful study of endogenous peptides.  
5.1. The CSF endopeptidome 
More than 18.000 endogenous CSF peptides were identified by means of extensive sample preparation 
and state of the art analysis instrumentation. The most likely reason for the high number of 
identifications, compared to previous trials, is primarily that the method based on pre-fractionation 
reduced sample complexity and allowed for an increased total volume of CSF in the sample; both factors 
combined to improve the ability to study low-abundant analytes.  
Further, by employing alternative search strategies, such as combining identifications resulting from 
three different peptide identification algorithms or performing spectral clustering prior to identification 
– we avoided losing, or rather, avoided not using, a large section of the MS/MS data. Most importantly, 
we could show that the combination of search algorithms could be performed while keeping peptide IDs 
resulting from multiple testing within the boundaries set by the employed FDR-level. That is, at the set 
FDR of 1% one could expect the number of diverging peptide IDs (PSMs) when combining two different 
search algorithms to be between 0 and 2%, everything above this would be expected to be the result of 
multiple testing. Since the 2%-boundary was never crossed it was not possible to deduce whether the 
peptide IDs were the result of multiple testing or a discrepancy between search algorithms. Thus, our 
approach was within the tolerable margin of error. 
The quantitation-driven approach to biomarker discovery, spectral clustering, proved to be equally 
useful and labour intensive. Although the method needs further development, the advantage of allowing 
for discovery of quantitative differences in analytes, even with minimal information, is obvious. Since 
we were able to show that the identity of the peptide in question could eventually be ascertained, we 
proved that taking this route was useful both as a stand-alone approach and as compliment to traditional 
discovery proteomics/peptidomics. Possibly one of the greatest advantages however, stem from this 
strategy allowing for the researcher to be more unbiassed since the analyte in question remains 
unidentified until further analysis. This fact is not to be frown upon since experience tells me that once 
the protein origin is established one tends to pick favourites; for instance, everything with the prefix 
“neuro” makes your heart run a little bit faster.  
The ability to explore and quantify the peptides in the lower concentration-ranges of CSF could prove 
to be the key to discovering the initial signs of neurodegeneration. Although diseases such as AD 
eventually ends up reducing large parts of the CNS to rubble, the pre-clinical stage is believed to be 
decades long and the initial pathological process thus most likely leave only faint traces. If AD is ever 
to be treatable it is necessary to understand these early processes, as well as being able to start treatment 
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as soon as possible. Since cognitive decline is the main clinical feature of AD, and we so far have no 
ability to repair a broken brain, a late-stage treatment of AD is simply not appealing. Hence, we believe 
that the findings and methods presented here may be of use in later studies of NDs and the general study 
of the CSF/CNS.   
A last comment on these discoveries, mainly added because there has been some degree of push-back 
against the very concept of studying endogenous peptides. We are of course biased in the discussion of 
the potential usefulness of endogenous CSF peptides, but well-established facts say there is a large 
number of bioactive endogenous peptides, among them insulin, Aβ1-42 and various CNS signal 
substances. Further, a large section of the endogenous peptides discovered in CSF are the results of 
CNS-processing and are hence on some level indicative of the state of the CNS. Finally, the expanded 
CSF peptidome presented here has simply not been studied sufficiently to give an indication, positive 
or negative, of its overall usefulness, only that there are more endogenous peptides than previously 
shown.  Hence; we consider that the belief that the endopeptidome is to be discarded as simply a group 
of randomly generated waste products to be far from proven. However, if we are in the wrong and this 
is actually the case, the peptidome would still cause trouble for proteomics studies. Particularly those 
proteomics studies employing quantitation since many of the endogenous peptides present in the sample 
would look as if they were generated through proteolytic degradation and be quantified as such – thereby 
resulting in greater or lesser measurement errors. 
5.2. The peptides 
In paper II and III, we reported on the targeted analysis of the endogenous peptides; tau 175-190, P-tau 
175-190 and PTN 151-166. Their usefulness in the diagnosis and study of AD (and to some extent in 
other NDs) was evaluated in clinical cohorts and compared to and with the current core biomarkers. In 
the case of the two tau peptides we noted that their implementation as normalisers of their respective 
protein counterparts could allow for improved group separation and diagnostic accuracy. The PTN 
peptide by itself was able to separate AD from controls with an 80% accuracy which, albeit less accurate 
than the core biomarkers, shows potential.  
In paper I, we discovered a large number of endogenous peptides stemming from apolipoprotein E, a 
protein which three most common isoforms have a noted protective, neutral or negative impact on AD 
development, respectively. The gene coding for the protein constitute one of the few known genetic 
factors impacting AD and is thus of some interest in the study of the disease. The alteration of two 
separate amino acids in the protein sequence determine which of the three isoforms is primarily 
expressed, and thus which role the protein has in the disease. Endogenous peptides spanning both sites 
were discovered during the exploration of the CSF endopeptidome, and although this study is still on 
the “to-do” list the implication is clear; genotyping by means of endogenous peptides could be possible. 
These examples suggest that, even though the implementation is not always as straight forward, the 
endogenous peptides can be employed in various ways to ascertain information about the state of the 
CNS. Since the consensus is that all NDs, and AD in particular, are difficult study subjects with a myriad 
of complicating factors tied to them it might be necessary to introduce more complex diagnostic 
approaches. Combining peptidomics and proteomics and taking advantage of the fact that the two yield 
information on different parts of the whole might do the trick.     
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 Future perspectives 
From where and from what processes do all these endogenous peptides originate? Suggested sources 
include the proteasome as a major contributor, but it is possible that various pathological processes can 
be attributed as well. Further, as has previously been discussed and re-iterated, there are plenty of 
bioactive endogenous peptides which are the result of normal and highly specific processes. The latter 
two were at least officially the focus of the initial studies performed in this thesis. The study of the 
proteasomal involvement in peptide origin could start with observations of media from neuronal cell 
cultures of induced pluripotent stem (IPS) cell lines, wherein the proteasomal system can be artificially 
regulated. However; since the number of endogenous peptides is so large it will most likely prove 
difficult to determine the exact impact of proteasomal regulation. It is worth a shot, but it is quite possible 
that the origin of endogenous peptides might have to be determined on an individual peptide basis.  
Further expansion of the CSF endopeptidome. Although a large number of peptides were identified 
employing the reported methods, it is reasonable to believe there were groups of peptides that for various 
reasons remained undetected/unidentified. As was previously discussed, losses occur at every 
preparation step. The losses are either general, e.g., peptides adhering to the surface of an Eppendorf 
tube, or specific, as for instance during chromatographic peptide separation when the most 
hydrophobic/hydrophilic peptides either pass right over the column or are too strongly retained to elute 
with the gradient. And again, and lastly; not all detected peptides are identified. 
In peptidomics, since the peptides are not meant to directly infer information on a protein, every unique 
identification is potentially valuable in itself. Therefore, are all peptides of potential interest and the CSF 
peptidome should be further scrutinized. We suggest performing further studies employing several 
fractionation steps including strong anion/cation exchange (SAX/SCX), isoelectric focusing. Further, 
the peptides studied here were relatively small and it is possible that bioactive endogenous peptides are 
generally larger. For this purpose, steps to acquire and detect larger analytes should be taken. 
Suggestions include trying out MWCO-filters with larger pores (very simple alteration but might have 
an impact), employ ETD/EThcD as MS-fragmentation method, perform MS/MS on a high resolving 
TOF-instrument etc.          
Implementation of TFC in sample preparation for clinical routine, or at least develop the method so it is 
ready when there are some endogenous peptide biomarkers available. There are a few hurdles to 
overcome, such as reducing the concentration of organic component between eluting the peptides from 
the TFC column and loading them on the separation column. Also, as hinted before, a few biomarkers 
for the proposed assay would not come amiss. 
Lastly, a great number of endogenous peptides were discovered during our trials, and there is both 
qualitative and quantitative data available on a large section of these peptides. Further, in Paper III we 
presented a table of 20 clusters with promising quantitative differences between AD and controls. Only 
five of these peptides were eventually properly identified and only PTN 151-166 was further studied. 
There might be a slight tendency in omics to get a bit carried away with trying out new ways of 
generating larger and larger datasets, but the lowest hanging fruit might be to perform a thorough study 
of the candidates already identified.       
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